[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 177
1. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Cytology of the pleural effusion showed no malignant cells.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Adjuvant chemotherapy with carboplatin and paclitaxel was prescribed postoperatively, but the malignancy was not controlled due to lung, brain and vulva metastases.
  • CONCLUSION: The coexistence of primary neoplasms in the ovary and cervix is rare.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


2. Torng PL, Lin CW, Chan MW, Yang HW, Huang SC, Lin CT: Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma. Mol Cancer; 2009;8:120
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.
  • Promoter methylation has been linked to gene silencing and cancer progression.
  • We studied the correlation between IGFBP-3 and p53 expression as well as IGFBP-3 promoter methylation in ovarian endometrioid carcinoma (OEC) by immunohistochemical staining and quantitative methylation-specific PCR (qMSP).
  • CONCLUSION: Our data suggests that IGFBP-3 silencing through IGFBP-3 promoter methylation in the absence of p53 overexpression is associated with cancer progression.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. DNA Methylation. Insulin-Like Growth Factor Binding Protein 3 / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):566-73 [17096329.001]
  • [Cites] J Clin Pathol. 2009 Sep;62(9):777-85 [18977806.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2137-47 [17952116.001]
  • [Cites] APMIS. 2008 May;116(5):400-9 [18452430.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Oct;68(1):1-11 [18430583.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Mol Genet Metab. 2000 Jun;70(2):85-98 [10873390.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):448-53 [11054675.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39174-81 [10998426.001]
  • [Cites] Cancer. 2001 Dec 25;93(6):376-80 [11748577.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):149-58 [11804742.001]
  • [Cites] Endocr Rev. 2002 Dec;23(6):824-54 [12466191.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3669-75 [12473575.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):559-67 [14766248.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6569-80 [15247904.001]
  • [Cites] Nat Genet. 1992 Apr;1(1):45-9 [1301998.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):646-9 [7566179.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 12):40-7 [8941409.001]
  • [Cites] Oncogene. 1997 Jan 9;14(1):85-94 [9010235.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):892-8 [9307189.001]
  • [Cites] BMC Cancer. 2005 Jan 20;5:9 [15661074.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3568-74 [15769996.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7376-83 [16243810.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):210-8 [16445635.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):299-308 [16773633.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24588-601 [16793770.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):487-95 [18834621.001]
  • [Cites] Neoplasia. 2007 Dec;9(12):1091-8 [18084616.001]
  • (PMID = 20003326.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2799391
  •  go-up   go-down


3. van Niekerk CC, Bulten J, Vooijs GP, Verbeek AL: The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium. Obstet Gynecol Int; 2010;2010:465162

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium.
  • Objective. Ovarian and endometrial cancers coincide rather frequently in the same patient.
  • Methods. Using the national pathology database (PALGA) information of ovarian cancers and of earlier or later cancer in the endometrium was obtained.
  • 5366 Patients were identified with primary malignant epithelial or borderline malignancy.
  • Among 460 ovarian endometrioid carcinoma patients 53 cases showed a second primary endometrial cancer; 40 out of these 53 cases (75.5%) showed at both organ sites an endometrioid adenocarcinoma.
  • Conclusion. These findings suggest an important role for the endometrioid subtype and prompt to mechanism-based studies incorporating molecular techniques.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9344-50 [16361634.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):384-8 [17277759.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Nov;51(2):141-6 [8635635.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):456-62 [15297188.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(1):90-5 [14687794.001]
  • [Cites] Diagn Mol Pathol. 2003 Jun;12(2):71-8 [12766611.001]
  • [Cites] Cancer. 2003 May 15;97(10):2432-9 [12733142.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jan-Feb;13(1):32-7 [12631217.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):529-33 [11709271.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):355-62 [11606097.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2577-83 [9829719.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jan-Feb;18(1):159-64 [17506847.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):399-406 [18334710.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):783-9 [19305320.001]
  • (PMID = 20052276.001).
  • [ISSN] 1687-9597
  • [Journal-full-title] Obstetrics and gynecology international
  • [ISO-abbreviation] Obstet Gynecol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2796219
  •  go-up   go-down


Advertisement
4. Körner M, Burckhardt E, Mazzucchelli L: Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: A possible link to endometrioid adenocarcinoma. Mod Pathol; 2006 Dec;19(12):1615-23
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: A possible link to endometrioid adenocarcinoma.
  • Endometriosis may progress to invasive endometrioid adenocarcinoma, particularly in the ovary.
  • Up to now, little is known of the molecular mechanisms possibly involved in the malignant transformation of endometriosis.
  • Therefore, in this study, extragonadal endometriosis (n = 10), ovarian endometriosis without malignancy (n = 10), ovarian endometriosis with direct transition into endometrioid adenocarcinoma (n = 8), and normal endometrium (n = 12) were investigated for numerical chromosomal aberrations by fluorescence in situ hybridization using centromere enumeration probes.
  • Trisomies 1 and 7, and monosomies 9 and 17 were found in endometriosis, ovarian endometrioid adenocarcinoma, and normal endometrium.
  • The proportions of aneusomic cells were significantly higher in ovarian endometrioid carcinoma compared with ovarian endometriosis (P < 0.001), and in ovarian endometriosis compared with extragonadal endometriosis and normal endometrium (P < 0.001).
  • The data provide new evidence of a common lineage of endometriosis and ovarian endometrioid carcinoma.
  • The higher frequency of chromosomal aberrations in endometrioid carcinoma than in endometriosis may reflect an expansion of aberrant cell clones already present in endometriosis during the progression to cancer.
  • The higher frequency of chromosomal aberrations in ovarian endometriosis than in extragonadal endometriosis suggests a role of the ovarian stromal milieu in the induction of genetic changes, which may eventually lead to invasive cancer.
  • [MeSH-major] Aneuploidy. Carcinoma, Endometrioid / genetics. Endometriosis / genetics. Ovarian Neoplasms / genetics. Precancerous Conditions / genetics

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980942.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


5. Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR: Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn; 2006 Feb;8(1):76-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma.
  • However, these pathways remain unexplored in ovarian endometrioid adenocarcinoma (OEA).
  • Expression values were normalized to uninvolved ovarian epithelium.
  • Amplification of RNA from FPE tissues was not successful.
  • The expression of Desert hedgehog (DHH), Indian hedgehog (IHH), Hedge-hog interacting protein (HHIP), Wnt10B, Wnt9B, and Wnt inhibitory factor (WIF1) were tumor-specific with no detectable expression in normal ovarian epithelium.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Dec 20;18(55):7844-51 [10630637.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8247-55 [11719457.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2741-9 [12072409.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2215-20 [12174906.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4393-7 [12414986.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2435-45 [12460789.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Cancer. 2003 May 15;97(10 Suppl):2648-59 [12733130.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Development. 2003 Nov;130(22):5297-305 [14530294.001]
  • [Cites] Lancet. 1989 Jun 17;1(8651):1391 [2567404.001]
  • [Cites] J Clin Pathol. 1990 Jun;43(6):499-504 [1696290.001]
  • [Cites] Biotechniques. 1991 Sep;11(3):304, 306, 308 [1718327.001]
  • [Cites] Biotechniques. 1993 Mar;14(3):448-53 [7681300.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 12):40-7 [8941409.001]
  • [Cites] Methods Mol Biol. 1998;86:23-6 [9664448.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Mol Carcinog. 1999 Jun;25(2):86-91 [10365909.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):224-9 [14710233.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):559-67 [14766248.001]
  • [Cites] Chin Med Sci J. 2004 Mar;19(1):25-30 [15104221.001]
  • [Cites] Oncology. 2004;66(4):310-5 [15218299.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • (PMID = 16436637.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA086359-06; United States / NCI NIH HHS / CA / P20 CA101955; United States / NCI NIH HHS / CA / CA101955-01; United States / NCI NIH HHS / CA / P50 CA101955; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fixatives; 0 / Hedgehog Proteins; 0 / Trans-Activators; 0 / Wnt Proteins; 1HG84L3525 / Formaldehyde
  • [Other-IDs] NLM/ PMC1867577
  •  go-up   go-down


6. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR: Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell; 2007 Apr;11(4):321-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
  • One histologic subtype of ovarian carcinoma, ovarian endometrioid adenocarcinoma (OEA), frequently harbors mutations that constitutively activate Wnt/beta-catenin-dependent signaling.
  • Deregulation of these two pathways in the murine ovarian surface epithelium by conditional inactivation of the Pten and Apc tumor suppressor genes results in the formation of adenocarcinomas morphologically similar to human OEAs with 100% penetrance, short latency, and rapid progression to metastatic disease in upwards of 75% of mice.
  • [MeSH-major] Disease Models, Animal. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / genetics. Phosphatidylinositol 3-Kinases / genetics. Signal Transduction. Wnt1 Protein / genetics. beta Catenin / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenomatous Polyposis Coli Protein / genetics. Adenomatous Polyposis Coli Protein / physiology. Animals. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelium / metabolism. Epithelium / pathology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Mice. Mutation. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Ovary / metabolism. Ovary / pathology. Survival Rate. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


7. Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J: Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol; 2010 Jan;23(1):113-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary.
  • Mutations in the beta-catenin gene are common in ovarian endometrioid carcinoma.
  • The purpose of this study was to retrospectively assess the expression of beta-catenin in ovarian endometrioid carcinoma and correlate its expression with the Gynecologic Oncology Group's (GOG) grading system, clinicopathological characteristics, and patient survival.
  • A total of 49 patients with primary ovarian endometrioid carcinoma were included in this study.
  • We found that a low membranous expression of beta-catenin and a high mitotic count (>15 per 10 high-power fields) were significantly associated with poor prognosis and early recurrence of ovarian endometrioid carcinoma.
  • Young age at the time of diagnosis, advanced disease stage, and suboptimal debulking were among the clinical factors predicting poor survival and early disease recurrence.
  • The presence of squamous differentiation, a papillary pattern or nuclear pleomorphism did not show any correlation with overall survival or disease-free survival.
  • Low membranous expression of beta-catenin and high mitotic count are poor prognostic indicators in patients with ovarian endometrioid carcinoma, whereas the GOG grading system showed no prognostic value.
  • Our data suggest that there is a need to define a better grading system for ovarian endometrioid carcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820688.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA131183; United States / NCI NIH HHS / CA / CA016672; United States / NCI NIH HHS / CA / IP50CA83638
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  •  go-up   go-down


8. Ivanov S, Batashki I: [Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer]. Akush Ginekol (Sofiia); 2008;47(5):9-11
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer].
  • AIM: The ovarian cancer is the most malignant disease from all oncogynecological localizations.
  • The aim of our research work was to evaluate if the endometrioid cancer of the ovary has a different prognosis from the serous ovarian cancer.
  • The patients with endometrioid ovarian cancer (42) were matched with the patients with serous ovarian cancer (42).
  • RESULTS: 84 patients (42 with endometrioid cancer and 42 with serous ovarian cancer) were evaluated for 5 years period.
  • The five years survival of the patients with endometrioid ovarian cancer was 62% while the five years survival for patients with serous ovarian cancer was 72%.
  • In patients with endometrioid ovarian cancer the mean survival rate was 58 months, and for patients with serous ovarian cancer 70 months (P=0.30).
  • The estrogen receptor levels were not statistically significant between the two groups (P=0.110), while the progesteron receptor levels were statistically different (P<0.002).
  • CONCLUSIONS: In patients with endometrioid and serous ovarian cancer, while taking into consideration the age, grading, stage and level of cytoreduction--there is no difference for the five years survival or the length of survival.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227770.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


9. Valenzuela P, Ramos P, Redondo S, Cabrera Y, Alvarez I, Ruiz A: Endometrioid adenocarcinoma of the ovary and endometriosis. Eur J Obstet Gynecol Reprod Biol; 2007 Sep;134(1):83-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma of the ovary and endometriosis.
  • OBJECTIVE: We present a retrospective analysis of 22 cases of endometrioid ovarian carcinoma, reviewed to identify endometriosis and its malignant transformation.
  • STUDY DESIGN: Twenty-two patients with endometrioid ovarian cancer were included in the review.
  • The origin of the tumours was considered endometriosis-related when the presence of malignant changes in endometriosis glands leading to endometrioid carcinoma were found.
  • One of them presented a clearly benign to malignant transformation area.
  • In the third, a pre-menopausal woman, ovarian endometriosis with only focal endometrioid carcinoma was observed.
  • The three of them had a clear-cell carcinoma component.
  • In the remaining of the patients, CA 125 value did not exceed 35 U/ml.
  • CONCLUSION: Although this association is not very frequent, patients with ovarian endometriosis and a high CA 125 serum level should be managed with special care, regardless of their pre-menopausal or post-menopausal status.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Carcinoma, Endometrioid / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844279.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


10. Petersen M, Meyer F, Kalinski T, Bischoff J, Bohr UR, Lippert H: [Rare neuroendocrine carcinoma of the gall bladder. Coincidental occurrence of an endometrioid ovarian adenocarcinoma]. Dtsch Med Wochenschr; 2009 Jan;134(1-2):19-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare neuroendocrine carcinoma of the gall bladder. Coincidental occurrence of an endometrioid ovarian adenocarcinoma].
  • [Transliterated title] Seltenes neuroendokrines Karzinom der Gallenblase. Abgrenzung zur metachronen Koinzidenz mit einem endometrioiden Adenokarzinom des Ovars.
  • HISTORY AND CLINICAL FINDINGS: The histological investigation of a surgical specimen (after cholecystectomy) from a 73-year-old woman revealed a poorly differentiated carcinoma with glandular structures and a lymph node metastasis.
  • INVESTIGATIONS: Comparative immunochemistry, done to exclude metastatic growth of the previously demonstrated endometrioid ovarian carcinoma, was (1) negative for CK7 and CA125, positive for CK20, chromogranin A and synaptophysin (gall bladder and lymph node metastasis);.
  • (2) positive for CK7 and CA125, negative for CK20, chromogranin A and synaptophysin (ovary).
  • DIAGNOSIS: The tumor lesion within the gall bladder and lymph node was classified as a neuroendocrine carcinoma, not a metastasis of the ovarian carcinoma.
  • After 14 months another metastasis of the neuroendocrine carcinoma of the gall bladder was found.
  • But for eight years there has been no recurrence of the endometrioid adenocarcinoma of the left ovary.
  • CONCLUSION: Because of the increasing incidence of malignant diseases and second neoplasms there is a growing need for such diagnostic tests as histological and immunohistochemical analysis.
  • This is the first case, according to the available literature, of an endometrioid adenocarcinoma of the ovary concomitant with a neuroendocrine carcinoma of the gall bladder.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Gallbladder Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dtsch Med Wochenschr. 2019 Sep;134(39):1915
  • (PMID = 19090447.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Czeczuga-Semeniuk E, Bielawski T, Lemancewicz D, Rusak M, Wołczyński S: Vitamin A family compounds, estradiol, and docetaxel in proliferation, apoptosis and immunocytochemical profile of human ovary endometrioid cancer cell line CRL-11731. Folia Histochem Cytobiol; 2009;47(5):S127-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin A family compounds, estradiol, and docetaxel in proliferation, apoptosis and immunocytochemical profile of human ovary endometrioid cancer cell line CRL-11731.
  • Endometrioid carcinoma represents approximately 10% of cases of the malignant ovarian epithelial tumors.
  • According to literature, the vitamin A (carotenoids and retinoids) plays an essential role in cell proliferation, differentiation and apoptosis in both normal and neoplastic ovarian tissues.
  • Apart from that, the retinoids alter a cytotoxic effect of chemiotherapeutics, i.e. docetaxel, on ovarian cancer cell lines.
  • Retinoids act on cancer cells throughout different mechanism than taxanes, so they may be the potential candidates for the new treatment strategies of ovarian cancer.
  • The aim of the study was to determine the effects of vitamin A family compounds (retinol, beta-carotene, lycopene, all-trans -, 9-cis - and 13-cis retinoic acid) on the growth and proliferation of CRL-11731 endometrioid ovary cancer cell line and on docetaxel and estradiol activity in this culture.
  • Among vitamin A family compounds retinol and carotenoids, but not retinoids, inhibited the growth of cancer cells in dose dependent manner.
  • Only the concentration of 100 muM of docetaxel inhibited incorporation [3H] thymidine into CRL-11731 cancer cells.
  • The results of our study justified an important role of vitamin A in the pathophysiology of the ovarian endometrioid cancer.

  • MedlinePlus Health Information. consumer health - Vitamin A.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. VITAMIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067883.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 11103-57-4 / Vitamin A; 4TI98Z838E / Estradiol
  •  go-up   go-down


12. Kitajima K, Kaji Y, Kuwata Y, Imanaka K, Sugihara R, Sugimura K: Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary. Radiat Med; 2007 Aug 1;25(7):346-54
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary.
  • PURPOSE: We assessed magnetic resonance imaging (MRI) features and clinical characteristics of ovarian endometrioid adenocarcinoma.
  • MATERIALS AND METHODS: A total of 31 patients with 39 surgically proven ovarian endometrioid adenocarcinomas were analyzed retrospectively.
  • Histologically, 13 lesions in 12 patients arose from proven endometriomas (group A), and 26 lesions in 19 patients did not coexist with endometrioma (group B).
  • CONCLUSION: MRI of ovarian endometrioid adenocarcinomas revealed two types: a solid type and a cystic type.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Magnetic Resonance Imaging / methods. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705005.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


13. Abe A, Furumoto H, Yoshida K, Nishimura M, Irahara M, Kudo E, Sano T: A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component.
  • Endometrioid adenocarcinoma of the ovary coexists very rarely with yolk sac tumor (YST).
  • This unusual mixed tumor is thought to be a rare variant of endometrioid ovarian carcinoma because of its aggressive behavior, lack of response to chemotherapy, and unfavorable prognosis.
  • We report a case of ovarian endometrioid adenocarcinoma with a YST component in a postmenopausal woman.
  • Cytokeratin7 and epithelial membrane antigen were negative in YST, but positive in endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466041.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 1605-68-1 / taxane; 49DFR088MY / Platinum; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Geisler JP, Buller E, Manahan KJ: Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. Eur J Gynaecol Oncol; 2008;29(2):126-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary.
  • OBJECTIVE: The purpose of this study was to analyze estrogen receptor alpha and beta (ERalpha, ERbeta) expression in a stage and grade matched cohort of patients with serous and endometrioid adenocarcinoma of the ovary.
  • METHODS: Forty-two patients from 1991 to the present were found to have the diagnosis of endometrioid adenocarcinoma of the ovary and have tissue available for analysis.
  • These were stage and grade matched with ten patients having serous adenocarcinoma of the ovary during the same time period.
  • RESULTS: ERalpha expression was present in ten of ten endometrioid adenocarcinomas but in only five of ten serous carcinomas (chi2, p = 0.01).
  • ERbeta expression was present in six of ten endometrioid adenocarcinomas and in four of ten serous caricinomas (chi2, p = 0.65).
  • Methylation of the ERalpha and ERbeta CpG islands was found in tumors without mRNA expression but not in the tumors with mRNA expression (p = 0.005).
  • CONCLUSIONS: ERalpha expression, but not ERbeta expression, is significantly more common in endometrioid than serous adenocarcinomas of the ovary when controlled for stage and grade.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Estrogen Receptor alpha / genetics. Estrogen Receptor beta / genetics. Ovarian Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459544.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA 79445-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / RNA, Messenger
  •  go-up   go-down


15. Stolnicu S, Preda O, Dohan M, Puscasiu L, García-Galvis OF, Nogales FF: Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change. Int J Gynecol Pathol; 2008 Oct;27(4):521-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change.
  • A 42-year-old patient had a stage III ovarian endometrioid adenocarcinoma with areas of hepatoid carcinoma (HC) of clear cell and eosinophilic pseudoglandular type that was difficult to differentiate from endometrioid carcinoma of oxyphilic type and sex cord-stromal tumor.
  • Immunohistochemically, endometrioid adenocarcinoma was positive for CA125, estrogen and progesterone receptors, CAM5.2, cytokeratin (CK) 7 and 19, and vimentin.
  • HC areas were positive for hep par1, polyclonal carcinoembryonic antigens, CD10, alpha-fetoprotein, epithelial membrane antigens, and antimitochondrial antibodies and shared with endometrioid carcinoma focal CK7, and constant positive CK19, CAM5.2, and progesterone receptors.
  • In the differential diagnosis, a hepatic immunophenotype of oxyphilic, mitochondriae-rich areas (demonstrated by antimitochondrial antibodies) was identified by HC specific (hep par1) and characteristic markers: canalicular, cytoplasmic and membranous polyclonal carcinoembryonic antigens, CD10 patterns, and alpha-fetoprotein).
  • Trabecular and clear vacuolated areas of HC resembled luteinized cells of sex cord-stromal ovarian tumors, but the membranous positivity to CAM5.2 supported epithelial (hepatoid) identity.
  • The partial preservation of an endometrioid immunophenotype in HC (positive CK7 and 19 and progesterone receptors) would support an origin from endometrioid carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / pathology. Cell Differentiation / physiology. Female. Humans. Immunohistochemistry. Oxyphil Cells / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753970.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Miyai K, Yamamoto S, Aida S, Shimazaki H, Takano M, Kudoh K, Furuya K, Tamai S, Matsubara O: Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary. Int J Gynecol Pathol; 2010 Jul;29(4):321-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary.
  • We report a case of massive intra-abdominal undifferentiated carcinoma derived from a tiny well-differentiated endometrioid adenocarcinoma of the ovary.
  • Both ovaries were apparently normal in size, but a cut section of the right ovary revealed a 2-cm solid and cystic tumor showing focal rupture to the peritoneal surface.
  • The right ovarian tumor was a histologically well-differentiated endometrioid adenocarcinoma.
  • Both the intra-abdominal undifferentiated tumor and the ovarian adenocarcinoma cells were immunohistochemically positive for keratin AE1/3, Ber-EP4, and CD10.
  • Epithelial membrane antigen was positive only in the ovarian adenocarcinoma component, and vimentin was diffusely positive only in the intra-abdominal undifferentiated tumor component.
  • Allelotype analysis using 24 polymorphic markers located on 12 chromosomal arms showed that the intra-abdominal undifferentiated carcinoma and ovarian adenocarcinoma components had a high concordance rate (88%) of allelic patterns including identical allelic loss patterns at 7 chromosomal loci, suggesting a common genetic lineage.
  • These data suggest that ovarian endometrioid adenocarcinoma, even when small in size, can give rise to a massive undifferentiated carcinoma filling the peritoneal cavity.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567143.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / DNA, Neoplasm; 0 / KRTAP1-3 protein, human; 0 / Keratins, Hair-Specific; 0 / Mucin-1; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 0 / human epithelial antigen-125; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


17. Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM: Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol; 2010 Feb;220(3):392-400
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
  • The histopathological diagnosis of high-grade endometrioid and serous carcinoma of the ovary is poorly reproducible under the current morphology based classification system, especially for anaplastic, high-grade tumours.
  • The transcription factor Wilms' tumour-1 (WT1) is differentially expressed among the gynaecological epithelia from which epithelial ovarian cancers (EOCs) are believed to originate.
  • In EOCs, WT1 protein is observed in the majority of serous carcinomas and in up to 30% of endometrioid carcinomas.
  • It is unclear whether the latter is a reflection of the actual incidence of WT1 protein expression in endometrioid carcinomas, or whether a significant number of high-grade serous carcinomas have been misclassified as endometrioid carcinoma.
  • The aim of this study was to better define the molecular characteristics of serous and endometrioid carcinomas in an attempt to address the problems with the current histopathological classification methods.
  • Gene expression profiles were analysed to identify reproducible gene expression phenotypes for endometrioid and serous carcinomas.
  • It was found that nuclear WT1 protein expression can identify misclassified high-grade endometrioid carcinomas and these tumours should be reassigned to serous histotype.
  • Although low-grade endometrioid carcinomas rarely progress to high-grade carcinomas, a combined WT1-negative, TP53-positive immunophenotype may identify an uncommon high-grade subtype of ovarian endometrioid carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Cystadenocarcinoma, Serous / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [CommentIn] J Pathol. 2010 Sep;222(1):117; author reply 118 [20572050.001]
  • (PMID = 19967725.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE6008
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Neoplasm Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


18. Hayasaka T, Nakahara K, Kojimahara T, Saito-Sekiguchi M, Motoyama T, Kurachi H: Endometrioid adenocarcinoma with a functioning stroma. J Obstet Gynaecol Res; 2007 Jun;33(3):381-3
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma with a functioning stroma.
  • A case of a 70-year-old woman with endometrioid adenocarcinoma of the ovary with functioning stroma is presented.
  • The surgical specimens consisted of a multilocular cystic ovarian tumor of 95 mm in diameter and an enlarged uterus.
  • Histologically, the tumor was composed of proliferating, atypical, columnar cancer cells resembling early secretory endometrial cells, and condensation of plumed stromal cells resembling theca lutein cells.
  • The diagnosis of endometrial adenocarcinoma of the ovary with functioning stroma was made.
  • Almost all types of ovarian tumor have been reported to be associated with endocrine abnormalities.
  • Mucinous epithelial ovarian tumors most commonly present with estrogenic stroma, although the frequency of endometrioid adenocarcinoma with functioning stroma is very low.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Estradiol / blood. Follicle Stimulating Hormone / blood. Ovarian Neoplasms / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578372.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


19. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T: Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med; 2005 Jan;11(1):63-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.
  • Epithelial ovarian tumors present a complex clinical, diagnostic and therapeutic challenge because of the difficulty of early detection, lack of known precursor lesions and high mortality rates.
  • Endometrioid ovarian carcinomas are frequently associated with endometriosis, but the mechanism for this association remains unknown.
  • Here we present the first genetic models of peritoneal endometriosis and endometrioid ovarian adenocarcinoma in mice, both based on the activation of an oncogenic K-ras allele.
  • In addition, we find that expression of oncogenic K-ras or conditional Pten deletion within the ovarian surface epithelium gives rise to preneoplastic ovarian lesions with an endometrioid glandular morphology.
  • Furthermore, the combination of the two mutations in the ovary leads to the induction of invasive and widely metastatic endometrioid ovarian adenocarcinomas with complete penetrance and a disease latency of only 7 weeks.
  • The ovarian cancer model described in this study recapitulates the specific tumor histomorphology and metastatic potential of the human disease.
  • [MeSH-major] Disease Models, Animal. Endometriosis / genetics. Ovarian Neoplasms / genetics. Protein Tyrosine Phosphatases / genetics. Tumor Suppressor Proteins / genetics. ras Proteins / genetics


20. Uzan C, Darai E, Valent A, Graesslin O, Cortez A, Rouzier R, Vielh P: Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. Virchows Arch; 2009 May;454(5):525-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma.
  • A role for the EGF system, in particular HER1 and 2, in growth of the endometrium has been suggested but HER1 and 2 have not been studied in all locations of endometriosis and in ovarian endometrioid adenocarcinoma (OEC) which is a rare form of malignant transformation of endometriosis.
  • Immunohistochemistry (IHC) was used for studying HER1 and HER2 in ovarian (n = 10), peritoneal (n = 10), colorectal endometriosis (n = 20) and OEC (n = 10).
  • The other samples were 17 disomic without HER2 amplification; HER1 and 2 do not seem to have a role in endometriosis physiopathology.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometriosis / metabolism. Intestinal Diseases / metabolism. Ovarian Neoplasms / metabolism. Peritoneal Diseases / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism


21. Hashiguchi Y, Tsuda H, Bandera CA, Nishimura S, Inoue T, Kawamura N, Berkowitz RS, Mok SC: Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med Oncol; 2006;23(2):205-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer.
  • This study compared the DNA, RNA, and protein levels of osteopontin (OPN) in endometrioid endometrial cancer (EEC) and ovarian endometrioid cancer (OEC).
  • In total, 63 cancer cases (EEC: 33, OEC: 30) were included.
  • The correlation between relative mRNA and protein expression levels was significant in both the EECs and OECs; however, the correlation between relative DNA and mRNA levels was not significant.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Sialoglycoproteins / biosynthesis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720920.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


22. Wu TI, Chang TC, Hsueh S, Lai CH: Ovarian endometrioid carcinoma with diffuse pigmented peritoneal keratin granulomas: a case report and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):426-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian endometrioid carcinoma with diffuse pigmented peritoneal keratin granulomas: a case report and review of the literature.
  • The presence of keratin granulomas in peritoneal cavity associated with ovarian endometrioid carcinoma, which might be related to leakage from the ovarian tumor, is rarely reported.
  • Its clinical significance has not yet been well investigated.
  • The ovarian tumor was an endometrioid adenocarcinoma with squamous differentiation.
  • Since viable epithelial cells in the implants could be differentially identified against mesothelial or granulomatous components by CK-7 staining and DNA aneuploidy was demonstrated on primary ovarian tumor, four courses of chemotherapy were administered.
  • The patient has been free of disease for 18 months since diagnosis.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Granuloma / pathology. Lymph Nodes / pathology. Ovarian Neoplasms / pathology. Peritoneal Diseases / pathology
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Biopsy, Needle. Female. Flow Cytometry. Follow-Up Studies. Frozen Sections. Humans. Immunohistochemistry. Laparotomy. Middle Aged. Ovariectomy. Treatment Outcome


23. Umezu T, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Kikkawa F: Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity. Hum Cell; 2007 Aug;20(3):71-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity.
  • A new cell line (NOE) of human ovarian endometrioid carcinoma was established and characterized.
  • These results indicated that NOE cells showed similar chemosensitivity and properties to those of the original tumor and might be useful in basic studies on the diagnosis, treatment and etiology of ovarian tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Endometrioid / pathology. Cell Line, Tumor / drug effects. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - NOE (CVCL_W381) .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645726.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Fujibayashi M, Aiba M, Iizuka E, Igarashi A, Muraoka M, Takagi K: Granulosa cell tumor-like variant of endometrioid carcinoma of the ovary exhibiting nuclear clearing with biotin activity: a subtype showing close macroscopic, cytologic, and histologic similarity to adult granulosa cell tumor. Arch Pathol Lab Med; 2005 Oct;129(10):1288-94
Hazardous Substances Data Bank. BIOTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumor-like variant of endometrioid carcinoma of the ovary exhibiting nuclear clearing with biotin activity: a subtype showing close macroscopic, cytologic, and histologic similarity to adult granulosa cell tumor.
  • CONTEXT: The sex cord-like variant of endometrioid carcinoma of the ovary shows many similarities to Sertoli-Leydig cell tumor and granulosa cell tumor.
  • However, few cases of the granulosa cell tumor-like variant have been reported, suggesting this tumor might often be hidden under the diagnosis of granulosa cell tumor.
  • OBJECTIVE: To investigate the similarities and differences between the granulosa cell tumor-like variant of endometrioid carcinoma and granulosa cell tumor of the ovary and to evaluate a newly observed feature, namely, nuclear clearing (or optically clear nuclei), in this variant tumor.
  • DESIGN: A comparative macroscopic, cytologic, histopathologic, and immunohistochemical study in specimens obtained from the following patients: 1 patient with granulosa cell tumor-like variant of endometrioid carcinoma diagnosed by frozen section examination, 3 patients with granulosa cell tumor, and 6 patients with classic endometrioid carcinoma.
  • CONCLUSION: Because the granulosa cell tumor-like variant is pathologically similar to granulosa cell tumor, showing only some dissimilarities to the latter, it can easily be misdiagnosed if the possibility of this variant is not kept in mind.
  • Identification of the typical endometrioid histologic features or related lesions or immunohistochemistry may lead to a proper diagnosis.
  • The observation of nuclear clearing with biotin activity in nonmorular nests suggests that this tumor has endometrioid epithelial characteristics.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Nucleus / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biotin / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / pathology. Cytodiagnosis. Female. Humans. Immunoenzyme Techniques. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Pathol Lab Med. 2008 Aug;132(8):1222. Okamura, Mitsue [corrected to Muraoka, Mitsue]
  • (PMID = 16196518.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 6SO6U10H04 / Biotin
  •  go-up   go-down


25. Santillan A, Bristow RE: Paraneoplastic cerebellar degeneration in a woman with ovarian cancer. Nat Clin Pract Oncol; 2006 Feb;3(2):108-12; quiz 1 p following 112
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration in a woman with ovarian cancer.
  • During her initial admission, the patient improved to some degree and was discharged with a possible diagnosis of viral meningitis.
  • A general and gynecological examination was otherwise unremarkable.
  • DIAGNOSIS: Stage IIIC endometrioid adenocarcinoma of the ovary with paraneoplastic cerebellar degeneration.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Ovarian Neoplasms / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis


26. Henson DE, Schwartz AM, Tilara A, Grimley PM, Anderson WF: Population-based analysis of pathologic data: a new approach to the investigation of uterine endometrial and ovarian endometrioid carcinomas. Arch Pathol Lab Med; 2007 Sep;131(9):1337-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based analysis of pathologic data: a new approach to the investigation of uterine endometrial and ovarian endometrioid carcinomas.
  • CONTEXT: Population-based analysis of the histopathology of endometrioid adenocarcinoma of the endometrium and ovary combined with epidemiologic techniques offer a new approach to exploring the relationship of tumors that share a similar range of morphologic phenotypes.
  • Specifically, to test and compare whether the etiology/pathogenesis of ovarian endometrioid cancer is as dependent upon the reproductive environment as uterine endometrial carcinoma.
  • DESIGN: Graphic plots of the epidemiologic patterns were analyzed relating to incidence and age-specific rates of ovarian and uterine endometrioid carcinomas.
  • RESULTS: At all ages, uterine endometrioid carcinomas have higher incidence rates than their ovarian homologues.
  • In contrast, after age 50 (menopause), the incidence rates begin to diverge: the rates for uterine endometrial carcinomas continue to rise, whereas the rates for ovarian endometrioid carcinomas plateau.
  • Interestingly, endometrial stromal sarcomas follow an incidence rate pattern nearly identical to that of ovarian endometrioid carcinomas.
  • CONCLUSIONS: The continuum of cellular and molecular events predisposing to gynecologic cancers of endometrioid phenotype apparently cease to operate in the ovary after menopause, but additional cellular and molecular events appear to occur in the ageing uterine endometrium.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. SEER Program. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824787.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Pan Y, Kao MS: Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review. Curr Oncol; 2010 Nov;17(6):82-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.
  • Aromatase inhibitors have not been adequately assessed in treatment of ovarian cancer.
  • The aromatase inhibitor letrozole (2.5 mg daily) was administered in 2 cases of advanced endometrioid ovarian cancer with positive estrogen receptor.
  • CASE 1: A 52-year-old woman with a grade 2-3, stage iiic endometrioid ovarian cancer was optimally debulked and received 6 cycles of intravenous paclitaxel and intraperitoneal cisplatin-paclitaxel.
  • CASE 2: A 47-year-old woman with a grade 3, stage iiic endometrioid ovarian cancer was optimally debulked and treated with intravenous carboplatin-paclitaxel.
  • CONCLUSIONS: Endometrioid ovarian carcinoma may benefit from aromatase inhibitors, especially when the tumour burden is low after primary chemotherapy or when the inhibitor is used as maintenance therapy between chemotherapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151415.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2993449
  • [Keywords] NOTNLM ; Aromatase inhibitor / endometrioid ovarian cancer / letrozole / maintenance therapy / recurrent ovarian cancer
  •  go-up   go-down


28. Baize N, Mahamat A, Benizri E, Saint-Paul MC, Mounier N: Bone metastasis from endometrioid ovarian carcinoma: a case study and literature review. Eur J Gynaecol Oncol; 2009;30(3):326-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastasis from endometrioid ovarian carcinoma: a case study and literature review.
  • INTRODUCTION: Bone metastases from epithelial ovarian carcinoma are rare, usually discovered postmortem.
  • Furthermore, only two cases of endometrioid ovarian carcinoma with metastasis to the skeletal structures have been described in the literature.
  • CASE REPORT: We present the case of a 58-year-old woman with a lytic metastasis in the left iliac ramus from endometrioid ovarian carcinoma that occurred seven years after the initial diagnosis.
  • DISCUSSION: A review of the literature since 1966 on bone metastasis of ovarian cancer is also presented.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697633.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


29. Abbott KL, Lim JM, Wells L, Benigno BB, McDonald JF, Pierce M: Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics; 2010 Feb;10(3):470-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis.
  • Epithelial ovarian cancer is diagnosed less than 25% of the time when the cancer is confined to the ovary, leading to 5-year survival rates of less than 30%.
  • Therefore, there is an urgent need for early diagnostics for ovarian cancer.
  • Our study using glycotranscriptome comparative analysis of endometrioid ovarian cancer tissue and normal ovarian tissue led to the identification of distinct differences in the transcripts of a restricted set of glycosyltransferases involved in N-linked glycosylation.
  • In this study, we have extended our observations by the use of selected lectins to perform a targeted glycoproteomic analysis of ovarian cancer and normal ovarian tissues.
  • The glycoproteins that were verified were then analyzed further using existing microarray data obtained from benign ovarian adenomas, borderline ovarian adenocarcinomas, and malignant ovarian adenocarcinomas.
  • The verified glycoproteins found to be expressed above control levels in the microarray data sets were then screened for tumor-specific glycan modifications in serum from ovarian cancer patients.
  • Results obtained from two of these glycoprotein markers, periostin and thrombospondin, have confirmed that tumor-specific glycan changes can be used to distinguish ovarian cancer patient serum from normal serum.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 May;156(5):1549-56 [10793066.001]
  • [Cites] Environ Health Perspect. 2009 Jul;117(7):1116-23 [19654922.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):3898-906 [11034397.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):298-307 [11058770.001]
  • [Cites] Annu Rev Physiol. 2001;63:521-54 [11181966.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5792-800 [11313423.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17507-14 [11278670.001]
  • [Cites] Immunol Rev. 2001 Apr;180:5-15 [11414363.001]
  • [Cites] Mol Immunol. 2001 Aug;38(2-3):175-87 [11532279.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4141-5 [11591733.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2560-7 [11859152.001]
  • [Cites] Inhal Toxicol. 2002 May;14(5):459-86 [12028803.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42821-9 [12215441.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 15;31(20):e122 [14530455.001]
  • [Cites] Inhal Toxicol. 2003 Nov;15(13):1309-25 [14569495.001]
  • [Cites] J Allergy Clin Immunol. 2003 Nov;112(5):905-14 [14610479.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50781-90 [14522998.001]
  • [Cites] Clin Immunol. 2003 Dec;109(3):250-65 [14697739.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):119-25 [14726165.001]
  • [Cites] Science. 2004 Jun 11;304(5677):1678-82 [15192232.001]
  • [Cites] Physiol Genomics. 2004 Aug 11;18(3):261-72 [15173550.001]
  • [Cites] J Proteome Res. 2009 Apr;8(4):1631-8 [19714806.001]
  • [Cites] J Immunol. 2000 Jul 1;165(1):108-13 [10861042.001]
  • [Cites] Ann Surg. 1978 Dec;188(6):809-16 [736659.001]
  • [Cites] FEBS Lett. 1992 Dec 21;314(3):386-8 [1281792.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4807-14 [8648128.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2406-13 [9036991.001]
  • [Cites] J Exp Med. 1998 May 4;187(9):1537-42 [9565645.001]
  • [Cites] Genomics. 1998 Dec 1;54(2):316-22 [9828134.001]
  • [Cites] Methods Mol Biol. 1999;112:99-103 [10027233.001]
  • [Cites] J Allergy Clin Immunol. 2004 Nov;114(5):1116-23 [15536419.001]
  • [Cites] Electrophoresis. 2005 Jan;26(1):280-92 [15624150.001]
  • [Cites] Science. 2005 May 6;308(5723):804-6 [15879201.001]
  • [Cites] Electrophoresis. 2005 Jun;26(11):2092-108 [15880549.001]
  • [Cites] Immunol Rev. 2005 Aug;206:32-63 [16048541.001]
  • [Cites] Immunol Rev. 2005 Aug;206:83-99 [16048543.001]
  • [Cites] J Allergy Clin Immunol. 2006 Aug;118(2):455-65 [16890772.001]
  • [Cites] Clin Immunol. 2006 Nov;121(2):227-35 [16979384.001]
  • [Cites] J Radiat Res. 2007 Jan;48(1):39-44 [17229997.001]
  • [Cites] Inhal Toxicol. 2007;19 Suppl 1:117-26 [17886059.001]
  • [Cites] Proteomics. 2007 Nov;7(21):3906-18 [17922515.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Dec;37(6):706-19 [17630318.001]
  • [Cites] Arch Med Res. 2008 Aug;39(6):560-6 [18662586.001]
  • [Cites] J Hum Genet. 2008;53(8):728-38 [18566738.001]
  • [Cites] Clin Exp Allergy. 2008 Dec;38(12):1901-10 [19037965.001]
  • [Cites] Clin Immunol. 2009 Feb;130(2):186-98 [18955015.001]
  • [Cites] Yonsei Med J. 2009 Feb 28;50(1):22-30 [19259344.001]
  • [Cites] Annu Rev Physiol. 2009;71:489-507 [19575684.001]
  • [Cites] Hum Gene Ther. 2009 Dec;20(12):1597-606 [19548841.001]
  • (PMID = 19953551.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41RR018502; United States / NCI NIH HHS / CA / R01 CA064462; United States / NCRR NIH HHS / RR / P41 RR018502; United States / NCI NIH HHS / CA / U01 CA128454; United States / NCI NIH HHS / CA / UO1CA128454; United States / NCI NIH HHS / CA / R01CA064462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Proteome
  • [Other-IDs] NLM/ NIHMS793820; NLM/ PMC4932840
  •  go-up   go-down


30. Chen F, Shen K, Lang JH, Huang HF, Wu M: [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary]. Zhonghua Yi Xue Za Zhi; 2005 May 18;85(18):1257-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary].
  • OBJECTIVE: To investigate the clinical features, treatment and prognosis of patients with double primary carcinoma of uterine corpus and ovary.
  • METHODS: The clinical features, operation findings, treatment and prognosis of 36 patients with double primary carcinoma of uterine corpus diagnosed and treated in the last 20 years, 25 with typical endometrial adenocarcinoma and endometrioid carcinoma of the ovary (group A) 11 with non-endometrioid carcinoma in uterine corpus and/or ovary (group B) were respectively analyzed.
  • The 1, 3, and 5-year survival rates of these 36 patients were 89%, 83%, and 75% respectively, all equal to those of the patients with stage I ovarian cancer.
  • CONCLUSION: The prognosis of double primary carcinoma of uterine corpus and ovary is rather good.
  • It is necessary to distinguish double primary carcinoma of uterine corpus and ovary from stage II ovarian cancer and stage III endometrial carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029611.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Ozan H, Ozerkan K, Aker S, Bülbül M: A case with three primary tumors of the ovary, endometrium and gallbladder. Eur J Gynaecol Oncol; 2008;29(5):551-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case with three primary tumors of the ovary, endometrium and gallbladder.
  • A 52-year-old patient underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy, bilateral pelvic and paraaortic lymph node dissection, and partial omentectomy for endometrial carcinoma accompanied by an adnexal mass.
  • Histopathology revealed a uterine endometrioid adenocarcinoma, a mucinous adenocarcinoma of the gallbladder, and an ovarian endometrioid carcinoma with a clear cell component.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Gallbladder Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051835.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Misir A, Sur M: Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall. Arch Pathol Lab Med; 2007 Jun;131(6):979-81
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall.
  • Sertoliform endometrioid carcinoma of the ovary (SEC) is an uncommon variant that bears histologic similarity to Sertoli and Sertoli-Leydig cell tumors (SLTs).
  • A number of histologic features can be used to distinguish the 2 entities, the most important ones being (1) the presence of areas with the usual pattern of endometrioid carcinoma, and (2) the presence of mucin at the apical borders of the tumor cells.
  • Based on the clinicopathologic behavior of this entity, SEC should be considered a well-differentiated carcinoma with relatively good prognosis if limited to the ovary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Diagnostic Errors / prevention & control. Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adult. Aged. Carcinoid Tumor / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Krukenberg Tumor / diagnosis. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550331.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Hong DG, Chong GO, Seong WJ, Lee YS, Cho YL, Park JY, Chae JM, Park IS: A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman. Eur J Gynaecol Oncol; 2010;31(4):471-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman.
  • Ovarian yolk sac tumor (YST) is a malignant ovarian neoplasm differentiated from primordial germ cells that occur in young age, while endometrioid carcinoma (ECA) is a müllerian epithelial tumor that usually occurs in older patients.
  • The coexistence of an ovarian ECA and YST component is very rare.
  • The parts of both ovaries that showed an endometrioid-like glandular pattern were positive for cytokeratin 7 and negative for AFP, but the YST component was negative for cytokeratin 7 and positive for AFP.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882900.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


34. Geyer JT, López-García MA, Sánchez-Estevez C, Sarrió D, Moreno-Bueno G, Franceschetti I, Palacios J, Oliva E: Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol; 2009 Aug;33(8):1157-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
  • It has been recently suggested that ovarian serous carcinoma follows a dualistic pathway with low-grade carcinomas arising from borderline tumors and high-grade carcinomas originating de novo.
  • Similarly, our group has shown that based on their molecular profile endometrioid borderline tumors could predate low-grade endometrioid ovarian carcinomas (EOC).
  • It is not clearly understood if low-grade EOC is in turn related to high-grade EOC, or if high-grade EOC may also arise de novo.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542870.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW, Lin CT: Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene; 2008 Apr 3;27(15):2137-47
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma.
  • Metastasis and invasion occur in the majority of epithelial ovarian carcinoma at diagnosis.
  • To delineate the molecular signature in ovarian cancer invasion, we established and characterized a human ovarian endometrioid carcinoma (EC) cell line OVTW59-P0 and its invasion-related sublines (P1-P4, in the order of increasing invasive activity).
  • By microarray analysis of different gene expression among P0-P4 sublines, one group of gene was found negatively correlated with cancer invasion.
  • Re-expression of IGFBP-3 in P4 effectively inhibited cell migration, invasion and metastasis, but did not affect cell proliferation.
  • Our results provide evidence and indicate that IGFBP-3 plays an important role as an invasion-metastasis suppressor in ovarian EC.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Genes, Tumor Suppressor. Insulin-Like Growth Factor Binding Protein 3 / physiology. Ovarian Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952116.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3
  •  go-up   go-down


36. Lalich D, Tawfik O, Chapman J, Fraga G: Cutaneous metastasis of ovarian carcinoma with shadow cells mimicking a primary pilomatrical neoplasm. Am J Dermatopathol; 2010 Jul;32(5):500-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of ovarian carcinoma with shadow cells mimicking a primary pilomatrical neoplasm.
  • Shadow cells are characteristic of pilomatricoma, although they have been described in other cutaneous and visceral neoplasms, particularly endometrioid adenocarcinomas of the female genital tract.
  • We describe a metastasis of an ovarian endometrioid adenocarcinoma with shadow cells to the skin that was initially misinterpreted as a pilomatricoma.
  • We compare the histology of the ovarian neoplasm to 21 pilomatricomas.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / pathology. Pilomatrixoma / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Adult. Arm. Biopsy. Cell Differentiation. Diagnosis, Differential. Female. Humans. Ovariectomy. Ovary / pathology. Skin / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526175.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Stewart CJ, Brennan BA, Chan T, Netreba J: WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis. Pathology; 2008 Oct;40(6):592-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis.
  • AIMS: To determine how frequently endometrioid ovarian carcinomas (EOC) express WT1 protein, and to correlate the results with the presence of endometriosis and p53 immunoreactivity.
  • CONCLUSIONS: Nuclear WT1 expression is present in a minority of EOC and this should be considered if immunohistochemistry is used as an adjunct in sub-typing ovarian carcinomas.
  • The negative correlation of WT1 staining with endometriosis supports the possibility that some EOC, including unusual histological variants, arise from the ovarian surface epithelium.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometriosis / metabolism. Ovarian Neoplasms / metabolism. WT1 Proteins / biosynthesis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752126.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins
  •  go-up   go-down


38. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res; 2008 Aug 15;14(16):5198-208
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
  • PURPOSE: The study aim to identify novel molecular subtypes of ovarian cancer by gene expression profiling with linkage to clinical and pathologic features.
  • EXPERIMENTAL DESIGN: Microarray gene expression profiling was done on 285 serous and endometrioid tumors of the ovary, peritoneum, and fallopian tube.
  • Two subtypes represented predominantly serous low malignant potential and low-grade endometrioid subtypes, respectively.
  • The remaining four subtypes represented higher grade and advanced stage cancers of serous and endometrioid morphology.
  • Class prediction identified similar subtypes in an independent ovarian dataset with similar prognostic trends.
  • CONCLUSION: Gene expression profiling identified molecular subtypes of ovarian cancer of biological and clinical importance.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gene Expression Profiling. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology


39. Banz C, Ungethuem U, Kuban RJ, Diedrich K, Lengyel E, Hornung D: The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril; 2010 Sep;94(4):1212-7
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer.
  • OBJECTIVE: To determine whether endometriosis-associated endometrioid cancer (EAOC) is a specific entity compared with endometrioid cancer not associated with endometriosis (OC).
  • PATIENT(S): Seven patients with endometriosis-associated ovarian cancer EAOC and five patients each with OC, ovarian endometriosis, and benign ovaries.
  • INTERVENTION(S): Ovarian tissue samples were collected from surgical procedures.
  • These genes were equally regulated in endometriosis and EAOC but not in OC and benign ovaries.
  • They were equally regulated in EAOC and OC but not in ovarian endometriosis and benign ovaries.
  • That the second group is composed of genes that play a central role in cell-cell interaction, differentiation, and cell proliferation indicates that they may be important in the development of ovarian cancer in women with endometriosis.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometriosis / genetics. Gene Expression Profiling. Ovarian Diseases / genetics. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Endometriosis.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 19643405.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA111882
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS479538; NLM/ PMC4426869
  •  go-up   go-down


40. Nishimura N, Hachisuga T, Yokoyama M, Iwasaka T, Kawarabayashi T: Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary. J Obstet Gynaecol Res; 2005 Apr;31(2):120-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary.
  • AIM: To compare the survival and prognostic factors of patients with dual primary ovarian and endometrial cancers (primary group), and endometrial cancers metastatic to the ovaries (metastatic group).
  • METHODS: Thirty-six patients with gross tumors confined to the pelvis and of endometrioid adenocarcinoma subtype in both the endometrium and ovary were selected from our file of 546 Japanese women with endometrial carcinoma.
  • CONCLUSION: When encountering women with coexisting endometrioid carcinoma in the endometrium and ovary with gross tumor limited to the pelvis, more attention should be paid to LVSI of the tumor of the uterus as a poor prognostic indicator.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771637.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Nishimura S, Ito YM, Tsuda H, Ohnishi Y, Kataoka F, Nomura H, Chiyoda T, Suzuki A, Susumu N, Aoki D, Hatae M: The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol; 2010 Jan;148(1):67-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma.
  • OBJECTIVES: Endometrioid type adenocarcinoma sometimes occupies both endometrium and ovary and in some cases the origin cannot be determined.
  • STUDY DESIGN: In this study, we established a formula to distinguish ovarian endometrioid cancer (EOC) from endometrioid type endometrial cancer (EEC), based on our previous report of cyclin and KI67 expression pattern by immunohistochemistry of 36 EECc and 37 OECc by the logistic regression.
  • We calculated the diagnostic accuracy using 92 test samples retrospectively and finally could diagnose the origin of 16 cases in whom endometrioid type adenocarcinoma arose in both ovary and endometrium and could be determined by Scully's criteria, and 15 cases in whom endometrioid type adenocarcinoma arose in both ovary and endometrium and Scully's criteria were not useful retrospectively.
  • If Prob(EOC) is larger than 0.5, the diagnosis is ovarian cancer; if less than 0.5 it is endometrial cancer.
  • In the other 15 cases, 12 cases were judged as ovary/ovary, 2 cases were judged as uterus/uterus and 1 case was judged as uterus/ovary.
  • CONCLUSION: The formula we established was thought to be useful to distinguish the origin of the cases in whom endometrioid type adenocarcinoma arises in both ovary and endometrium.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815329.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CCNB1 protein, human; 0 / CCNF protein, human; 0 / Cyclin A; 0 / Cyclin B1; 0 / Cyclin E; 0 / Cyclins; 0 / Ki-67 Antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


42. Kauppila S, Altinörs M, Väre P, Liakka A, Knuuti E, Nissi R: Primary sex cord-like variant of endometrioid adenocarcinoma arising from endometriosis. APMIS; 2008 Sep;116(9):842-5
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sex cord-like variant of endometrioid adenocarcinoma arising from endometriosis.
  • Although endometriosis is a benign disease, some malignant tumors have been reported to develop in endometriotic lesions, most commonly in the ovary.
  • The relationship between endometriosis and malignancy is not well known, but the majority of endometriosis-associated ovarian malignancies are usually endometrioid adenocarcinomas and clear cell carcinomas.
  • The sex cord-like variant of endometrioid adenocarcinoma is a rare tumor that histologically closely resembles the sex cord-stromal tumor.
  • Despite its rarity, the correct histological diagnosis of the sex cord-like variant of endometrioid adenocarcinoma is crucial to avoid misdiagnosis of a less aggressive tumor.
  • We here report a 53-year-old woman who was diagnosed as having this very rare subtype of endometroid adenocarcinoma curiously arising from an endometriotic lesion at the site of previous salpingo-oophorectomy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024607.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


43. Hart WR: Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int; 2005 May;55(5):231-43
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms.
  • Secondary (metastatic) neoplasms to the ovary often cause diagnostic problems, especially those tumors that produce large, symptomatic ovarian tumors that masquerade clinically and pathologically as primary ovarian tumors of surface epithelial type.
  • Except for typical Krukenberg tumors, which usually originate in the stomach and generally are easily recognized, the most diagnostically problematic secondary ovarian tumors are those that originate in the large intestine, appendix, and pancreas.
  • Metastases from these sites typically produce histologic patterns resembling primary ovarian endometrioid carcinoma or mucinous epithelial neoplasms of borderline and malignant types.
  • This review focuses on the diagnostic challenge of distinguishing these secondary ovarian tumors from primary ovarian neoplasms.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenoma, Mucinous / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Appendiceal Neoplasms / pathology. Diagnosis, Differential. Female. Humans. Intestinal Neoplasms / pathology. Intestine, Large / pathology. Ovary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871720.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 243
  •  go-up   go-down


44. Keita M, Bessette P, Pelmus M, Ainmelk Y, Aris A: Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes. J Ovarian Res; 2010;3:3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes.
  • OBJECTIVES: Endometrioid carcinoma of the ovary is one of the most types of epithelial ovarian cancer associated to endometrioisis.
  • Endometrioid tumors as well as endometriotic implants are characterized by the presence of epithelial cells, stromal cells, or a combination of booth, that resemble the endometrial cells, suggesting a possible endometrial origin of these tumors.
  • Pro-inflammatory cytokines, including interleukin-1 (IL-1) have been reported to be involved in both endometriosis and ovarian carcinogenesis.
  • The major objective of this study was to determine the level expression of IL-1 ligands system (IL-1alpha, IL-1beta and IL-1RA) in the most common subtypes of ovarian cancer cells compared to endometrial cells.
  • METHODS: We used primary endometrial cells, endometrial cell line RL-952 and different subtypes of epithelial ovarian cancer cell lines including TOV-112D (endometrioid), TOV-21G (clear cell) and OV-90 (serous).
  • RESULTS: We demonstrated that IL-1 ligands were expressed by all endometriosis-associated ovarian cancer subtypes and endometrial cells.
  • In contrast to other cancer ovarian cells, endometrioid cells exhibit a specific decrease of cell-associated IL-1RA expression and its soluble secretion.
  • CONCLUSION: Endometrioid ovarian cancer exhibits an alteration in the expression of IL-1RA, a key protector against tumorogenic effects of IL-1.
  • This suggests a possible link between the endometrium, the tissue ectopic endometriosis and endometrioid ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytokine. 1996 Jul;8(7):578-85 [8891439.001]
  • [Cites] Hum Reprod. 1995 Sep;10(9):2472-7 [8530693.001]
  • [Cites] Mol Cell Endocrinol. 1994 May;101(1-2):307-14 [9397965.001]
  • [Cites] Annu Rev Immunol. 1998;16:27-55 [9597123.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):788-96 [9708947.001]
  • [Cites] J Reprod Immunol. 1998 Aug;39(1-2):117-31 [9786457.001]
  • [Cites] Cancer Lett. 1999 Aug 3;142(2):179-84 [10463774.001]
  • [Cites] Int J Oncol. 1999 Dec;15(6):1251-4 [10568836.001]
  • [Cites] Fertil Steril. 2000 Jan;73(1):166-70 [10632434.001]
  • [Cites] Mol Hum Reprod. 2000 Mar;6(3):269-75 [10694276.001]
  • [Cites] Adv Exp Med Biol. 2000;479:277-88 [10897428.001]
  • [Cites] Horm Res. 2000;53(6):300-4 [11146371.001]
  • [Cites] Fertil Steril. 2001 Mar;75(3):489-95 [11239529.001]
  • [Cites] Am J Reprod Immunol. 2001 Apr;45(4):193-9 [11327545.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3068-75 [11753986.001]
  • [Cites] Biol Reprod. 2002 Feb;66(2):401-6 [11804955.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:89-100; discussion 118, 396-406 [11949968.001]
  • [Cites] Obstet Gynecol. 2002 Oct;100(4):788-95 [12383550.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Hum Reprod. 2003 Mar;18(3):593-7 [12615831.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):502-16 [12835670.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Eur Cytokine Netw. 2003 Oct-Dec;14(4):246-55 [14715418.001]
  • [Cites] J Endocrinol. 2004 Feb;180(2):203-12 [14765973.001]
  • [Cites] Gynecol Obstet Invest. 2004;57(1):53-4 [14974460.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):641-8 [15286730.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5094-100 [15472211.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):331-41 [16473398.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1088-96 [16489061.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):387-408 [17043764.001]
  • [Cites] Reproduction. 2007 Jan;133(1):265-74 [17244752.001]
  • [Cites] Fertil Steril. 2007 Sep;88(3):594-9 [17292896.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1464-73 [17324958.001]
  • [Cites] J Reprod Immunol. 2008 Jan;77(1):75-84 [17517439.001]
  • [Cites] Reproduction. 2007 Sep;134(3):525-34 [17709570.001]
  • [Cites] PLoS Med. 2008 Dec 2;5(12):e232 [19053170.001]
  • [Cites] Fertil Steril. 1992 Mar;57(3):535-42 [1371258.001]
  • [Cites] Fertil Steril. 1992 May;57(5):990-7 [1374045.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2248-52 [1559228.001]
  • [Cites] Fertil Steril. 1991 May;55(5):952-7 [1827077.001]
  • [Cites] J Biol Chem. 1991 Jun 5;266(16):10331-6 [1828071.001]
  • [Cites] Prog Growth Factor Res. 1990;2(4):193-205 [2151936.001]
  • [Cites] J Clin Invest. 1994 Oct;94(4):1463-9 [7523451.001]
  • [Cites] Fertil Steril. 1993 Aug;60(2):276-9 [7687965.001]
  • [Cites] Biol Reprod. 1994 Sep;51(3):480-5 [7803619.001]
  • [Cites] Immunol Lett. 1993 Dec;39(1):45-52 [8144190.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2194-206 [8387543.001]
  • [Cites] Endocrinology. 1993 Nov;133(5):2391-4 [8404691.001]
  • [Cites] Br J Cancer. 1997;75(6):855-9 [9062407.001]
  • (PMID = 20181040.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2832771
  •  go-up   go-down


45. Nofech-Mozes S, Ghorab Z, Ismiil N, Ackerman I, Thomas G, Barbera L, Covens A, Khalifa MA: Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases. Am J Clin Pathol; 2008 Jan;129(1):110-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases.
  • We reviewed 827 consecutive cases of pure endometrial endometrioid adenocarcinoma (EEA) treated by hysterectomy to update the distribution of pathologic features.
  • Tumor grade (reported in a 2-tiered system), depth of myometrial invasion, presence of cervical involvement, lymphovascular invasion (LVI), and evidence of extrauterine disease were recorded.The median age at diagnosis was 62 years (range, 30-94 years).
  • Lymph nodes (sampled in 85 cases) were positive in 13 (1.6%), and ovarian metastases were present in 15 cases (1.8%).
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Nodes / pathology. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Ovarian Neoplasms / secondary. Ovary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089496.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Kulkarni JN, Gorasia TK, Choudhary JP, Mahajan PP: Endometrioid carcinoma of the upper urinary tract. J Cancer Res Ther; 2010 Oct-Dec;6(4):578-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinoma of the upper urinary tract.
  • Herein, we report a second case of endometrioid carcinoma of the upper urinary tract presenting 17 years after hysterectomy for high grade adenocarcinoma of ovary.
  • The histology showed endometrioid carcinoma of upper urinary tract without any evidence of endometriosis.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Urologic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21358108.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


47. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol; 2009 Jun;113(3):331-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
  • OBJECTIVE: We conducted the present study to clarify the clinicopathological characteristics of mucinous adenocarcinoma.
  • METHODS: Two hundred twenty-five patients were diagnosed with mucinous adenocarcinoma at individual institutes and underwent primary treatment between 1998 and 2003.
  • Of 189 patients undergoing central pathological review, 64 patients (33.9%) were diagnosed with mucinous invasive adenocarcinoma, 45 mucinous intraepithelial carcinoma, and 42 mucinous tumor of borderline malignancy.
  • Twenty-five patients were diagnosed with other histological subtypes, including 8 endometrioid adenocarcinoma, 5 clear cell carcinoma, 3 serous adenocarcinoma, and 4 mixed type.
  • There were 13 cases of metastatic mucinous adenocarcinoma, including 7 pseudomyxoma peritonei.
  • Four hundred thirty-three patients with serous adenocarcinoma were used as controls.
  • RESULTS: Forty-five patients with mucinous invasive carcinoma were in FIGO I-II stages and 19 in III-IV stages.
  • There was no difference in the outcome between mucinous invasive adenocarcinoma and serous adenocarcinoma in I-II stage patients and III-IV stage patients with optimal operation.
  • In contrast, patients with mucinous invasive adenocarcinoma receiving suboptimal operation showed a significantly worse prognosis (survival rate: 27.8% vs. 61.5%).
  • The response rate to chemotherapy for mucinous invasive adenocarcinoma was significantly lower than for serous adenocarcinoma (12.5% vs. 67.7%).
  • CONCLUSIONS: The diagnosis of mucinous invasive adenocarcinoma was difficult.
  • Since patients with mucinous invasive adenocarcinoma had a lower response to chemotherapy, aggressive cytoreductive surgery was an effective treatment to improve the prognosis for advanced stage patients.
  • A new chemotherapeutic regimen should be established for mucinous adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275957.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Akahane T, Sekizawa A, Okuda T, Kushima M, Saito H, Okai T: Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer. Int J Gynecol Pathol; 2005 Oct;24(4):369-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer.
  • Ovarian clear-cell carcinoma (OCCA) and ovarian endometrioid carcinoma (OEMC) are often associated with endometriosis.
  • This study determined the immunohistochemical expression of steroid hormone receptors and cancer-related genes in OCCA and OEMC specimens containing endometriosis and atypical endometriosis.
  • Pathological progression from endometriosis to atypical endometriosis to carcinoma was identified in 4 of 22 OCCAs and 4 of 16 OEMCs.
  • A gradual reduction in ERalpha and PRA expression was observed with malignant transformation from endometriosis to atypical endometriosis to OCCA.
  • In OEMC, ERalpha expression increased with malignant transformation.
  • Disappearance of hormone dependency might therefore be associated with malignant transformation to OCCA.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / pathology. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175084.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Estrogen Receptor alpha; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; 0 / progesterone receptor A; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


49. Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol; 2007 May;31(5):653-63
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
  • Distinction of primary ovarian epithelial tumors from metastatic adenocarcinomas is challenging for tumors exhibiting mucinous, endometrioid, or mixed endometrioid/mucinous differentiation.
  • Most endocervical adenocarcinomas exhibit mucinous and/or endometrioid differentiation; they infrequently metastasize to the ovaries but may simulate primary ovarian tumors [both atypical proliferative (borderline) and carcinoma].
  • The performance of this expression pattern for identifying metastatic endocervical adenocarcinomas in the ovaries among primary ovarian tumors and other metastatic adenocarcinomas having mucinous and/or endometrioid/endometrioidlike differentiation has not been evaluated.
  • Immunohistochemical expression of p16 was assessed in 195 tumors, including 98 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tumors), 93 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarcinomas of unknown origin (7 established as noncervical), and 4 adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin.
  • Mean and median expression values for HPV-positive endocervical adenocarcinomas (99%, 100%; range 90% to 100%) were substantially higher than those for primary ovarian mucinous (5%, 0%; range 0% to 70%) and endometrioid (20%, 10%; range 0% to 100%) tumors, HPV-unrelated endocervical adenocarcinomas (0%, 0%; range 0% to 60%), metastatic adenocarcinomas of unknown origin (11%, 0%; range 0% to 30%), and adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin (40%, 35%; range 0% to 90%); only the 15 HPV-positive endocervical adenocarcinomas and 6 other tumors had values of 80% or greater.
  • Diffuse (>75% positive tumor cells) moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical adenocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike differentiation. p16 is useful as part of a panel of immunohistochemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomaviridae / genetics. Papillomavirus Infections. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460447.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


50. Dai L, Li C, Shedden KA, Misek DE, Lubman DM: Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis. Electrophoresis; 2009 Apr;30(7):1119-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis.
  • The proteomic profiles from two distinct ovarian endometrioid tumor-derived cell lines, (MDAH-2774 and TOV-112D) each with different morphological characteristics and genetic mutations, have been studied.
  • Characterization of the differential global protein expression between these two cell lines has important implications for the understanding of the pathogenesis of ovarian endometrioid carcinoma.
  • Canonical pathway analysis using IPA demonstrates that important signaling pathways are highly associated with one of these two cell lines versus the other, such as the PI3K/AKT pathway, which is found to be significantly predominant in MDAH-2774 but not in TOV-112D.

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - MDAH 2774 (CVCL_0420) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - TOV-112D (CVCL_3612) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jan;82(1):142-50 [10638981.001]
  • [Cites] J Immunol. 2008 Apr 15;180(8):5575-81 [18390742.001]
  • [Cites] Nat Biotechnol. 2001 Mar;19(3):242-7 [11231557.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6617-26 [11641787.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8247-55 [11719457.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3068-75 [11753986.001]
  • [Cites] Proteomics. 2002 Jan;2(1):76-84 [11788994.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):927-43 [12959183.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Proteomics. 2004 Aug;4(8):2476-95 [15274142.001]
  • [Cites] Cancer. 1978 Nov;42(5):2352-9 [719612.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):717-21 [8795573.001]
  • [Cites] Curr Opin Oncol. 1997 Sep;9(5):465-70 [9327225.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):678-83 [9398045.001]
  • [Cites] Cytometry. 1999 Oct 15;38(5):201-13 [10516606.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] J Proteome Res. 2005 Jan-Feb;4(1):36-42 [15707355.001]
  • [Cites] Electrophoresis. 2005 Apr;26(7-8):1383-8 [15759303.001]
  • [Cites] Mol Cell Biochem. 2005 Jul;275(1-2):25-55 [16335783.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2186-94 [17441747.001]
  • [Cites] Brief Bioinform. 2008 Mar;9(2):156-65 [17905794.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2000 Jun;36(6):357-61 [10949993.001]
  • (PMID = 19288585.001).
  • [ISSN] 1522-2683
  • [Journal-full-title] Electrophoresis
  • [ISO-abbreviation] Electrophoresis
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM049500-12; United States / NCI NIH HHS / CA / R01 CA100104; United States / NIGMS NIH HHS / GM / R01GM49500; United States / NIGMS NIH HHS / GM / GM049500-12; United States / NIGMS NIH HHS / GM / R01 GM049500; United States / NCI NIH HHS / CA / R01CA100104; United States / NCI NIH HHS / CA / R01 CA100104-05; United States / NCI NIH HHS / CA / CA100104-05
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Proteome
  • [Other-IDs] NLM/ NIHMS80058; NLM/ PMC2674123
  •  go-up   go-down


51. Hoang CD, Boettcher AK, Jessurun J, Pambuccian SE, Bullard KM: An unusual rectosigmoid mass: endometrioid adenocarcinoma arising in colonic endometriosis: case report and literature review. Am Surg; 2005 Aug;71(8):694-7
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual rectosigmoid mass: endometrioid adenocarcinoma arising in colonic endometriosis: case report and literature review.
  • Malignant transformation is an infrequent complication of endometriosis.
  • The ovary is the primary site in 79 per cent of cases, and extragonadal sites are identified in 21 per cent.
  • Endometrioid carcinoma is a common histologic type that remains a diagnostic challenge-the main differential diagnosis includes colorectal carcinomas.
  • We report a case of malignant transformation arising in colonic endometriosis.
  • Immunohistochemical staining in addition to the usual histopathology was critical for accurate diagnosis of this endometriosis-associated intestinal tumor.
  • [MeSH-major] Carcinoma, Endometrioid / etiology. Colonic Diseases / complications. Endometriosis / complications. Rectal Neoplasms / etiology. Sigmoid Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217955.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


52. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • Low-grade endometrioid carcinomas, either of the endometrium or the ovaries, usually have an excellent prognosis.
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases.
  • Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary.
  • In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases.
  • In four cases, the diagnosis was made recently, with short follow-ups of 3 and 4 months.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Krepinska E, Kriz JT, Laco J: Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman. Eur J Gynaecol Oncol; 2010;31(5):584-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • Synchronous primary cancers of the endometrium and ovary occur in approximately 10% of all women with ovarian cancer and 5% of all women with endometrial cancer.
  • The pathogenesis of synchronous endometrial and ovarian cancer is unclear.
  • We report a case of unusual co-existence of endometroid adenocarcinoma of the uterus, serous borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061809.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


54. Testa AC, Timmerman D, Exacoustos C, Fruscella E, Van Holsbeke C, Bokor D, Arduini D, Scambia G, Ferrandina G: The role of CnTI-SonoVue in the diagnosis of ovarian masses with papillary projections: a preliminary study. Ultrasound Obstet Gynecol; 2007 May;29(5):512-6
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of CnTI-SonoVue in the diagnosis of ovarian masses with papillary projections: a preliminary study.
  • OBJECTIVES: To describe sonographically the distribution patterns of a second-generation contrast agent in the microcirculation of unilocular and multilocular ovarian masses with papillary projections, and to investigate whether qualitative evaluation of the passage of the contrast agent can improve the performance of sonography in distinguishing between benign and malignant masses with papillary projections.
  • METHODS: Thirty-three patients with unilocular or multilocular ovarian masses with papillary projections were enrolled into the study in three clinical centers.
  • RESULTS: Twenty-four (73%) lesions were benign, eight (24%) were borderline ovarian tumors, and one patient presented with an endometrioid ovarian adenocarcinoma.
  • CONCLUSION: Qualitative evaluation of blood circulation in papillary projections using CnTI-SonoVue examination does not improve the discrimination of benign from borderline/malignant ovarian masses with papillary projections.
  • [MeSH-major] Contrast Media. Ovarian Neoplasms / ultrasonography. Phospholipids. Sulfur Hexafluoride
  • [MeSH-minor] Adnexa Uteri / pathology. Adnexa Uteri / ultrasonography. Adult. Aged. Aged, 80 and over. Female. Humans. Image Enhancement / methods. Microbubbles. Microcirculation / ultrasonography. Middle Aged. Ovarian Cysts / pathology. Ovarian Cysts / ultrasonography. Ovary / pathology. Ovary / ultrasonography. Sensitivity and Specificity. Ultrasonography, Doppler, Color / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 ISUOG.
  • (PMID = 17444549.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


55. Cirpan T, Aygul S, Terek MC, Kazandi M, Dikmen Y, Zekioglu O, Sagol S: MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma. Eur J Gynaecol Oncol; 2007;28(4):278-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma.
  • OBJECTIVE: The aim of this study was to investigate the role of MMAC1 protein in the relationship between ovarian endometriosis and clear cell and endometrioid-type ovarian adenocarcinomas.
  • METHODS: A total of 63 subjects who underwent surgery for a pelvic tumoral mass, 30 of whom were diagnosed with grade 1 to 3 ovarian adenocarcinoma and 33 of whom were diagnosed with grade 1 to 4 endometriosis during histopathological examination were included in this study.
  • The mean age for subjects with ovarian endometrioid type adenocarcinoma was 51.8 +/- 12.4, whereas the mean age for subjects with ovarian clear cell type adenocarcinoma was 59.5 +/- 13.7.
  • Ovarian carcinomas were graded in accordance with the FIGO 1989 grading system.
  • RESULTS: Of the 63 subjects included in the immunohistochemical study, ovarian endometrioid adenocarcinoma was identified in 18 subjects, while 12 subjects were diagnosed with ovarian clear cell adenocarcinoma and 33 subjects with ovarian endometriosis.
  • No significant relationships were observed between age and MMAC immune staining in the ovarian endometrioid adenocarcinoma (r = -0.41, p = 0.08) and ovarian endometriosis (r = 0.12, p = 0.50) groups, whereas a significant relationship was observed in the ovarian clear cell adenocarcinoma group (r = 0.631, p = 0.02).
  • No significant relationships were observed between CA125 levels and MMAC immune staining in the ovarian endometrioide adenocarcinoma (r = 0.056, p = 0.82), ovarian endometriosis (r = 0.21, p = 0.36) and ovarian clear cell adenocarcinoma (r = 0.363, p = 0.24) groups.
  • No correlations were detected between MMAC immune staining and ovarian endometrioide adenocarcinoma or ovarian clear cell adenocarcinoma stage (r = -0.22, p = 0.37; r = 0.44, p = 0.14, respectively).
  • No significant relationships with respect to MMAC immune staining were detected between the endometriosis and ovarian clear cell adenocarcinoma groups (p = 0.05) and between the ovarian clear cell adenocarcinoma and ovarian endometrioid adenocarcinoma groups (p = 0.27).
  • A significant relationship with respect to MMAC immune staining was observed between ovarian endometrioide adenocarcinoma and endometriosis groups (p = 0.001).
  • CONCLUSION: Immunohistochemical determination of MMAC defective protein expressions could be considered for utilization as a new, simple and useful technique in determination of endometriosis patients with increased risk of malignant transformation, patients where early surgical treatment would be necessary and patients that should be subjected to follow-up controls with a higher frequency.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Endometriosis / genetics. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / metabolism
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Female. Genes, Tumor Suppressor / physiology. Humans. Immunohistochemistry. Middle Aged. Ovarian Diseases / diagnosis. Ovarian Diseases / genetics

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713092.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


56. Prat J: Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol; 2005 Feb;18 Suppl 2:S99-111
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinomas, including secondary tumors: diagnostically challenging areas.
  • The differential diagnosis of ovarian carcinomas, including secondary tumors, remains a challenging task.
  • Mucinous carcinomas of the ovary are rare and can be easily confused with metastatic mucinous carcinomas that may present clinically as a primary ovarian tumor.
  • International Federation of Gynecology and Obstetrics (FIGO) stage is the single most important prognostic factor, and stage I carcinomas have an excellent prognosis; FIGO stage is largely related to the histologic features of the ovarian tumors.
  • Metastatic colon cancer is frequent and often simulates ovarian endometrioid adenocarcinoma.
  • Although immunostains for cytokeratins 7 and 20 can be helpful in the differential diagnosis, they should always be interpreted in the light of all clinical information.
  • Occasionally, endometrioid carcinomas may exhibit a microglandular pattern simulating sex cord-stromal tumors.
  • However, typical endometrioid glands, squamous differentiation, or an adenofibroma component are each present in 75% of these tumors whereas immunostains for calretinin and alpha-inhibin are negative.
  • Endometrioid carcinoma of the ovary is associated in 15-20% of the cases with carcinoma of the endometrium.
  • Krukenberg tumors are metastatic adenocarcinomas traditionally perceived as composed of mucin-filled signet-ring cells associated with a striking proliferation of the ovarian stroma but many variations on this pattern occur.
  • [MeSH-major] Ovarian Neoplasms / pathology
  • [MeSH-minor] Base Sequence. Colonic Neoplasms / pathology. Cytoskeletal Proteins / genetics. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Keratin-20. Keratin-7. Keratins / analysis. Mutation. Prognosis. Trans-Activators / genetics. beta Catenin. ras Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492758.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 0 / beta Catenin; 68238-35-7 / Keratins; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 63
  •  go-up   go-down


57. Akahane T, Sekizawa A, Purwosunu Y, Nagatsuka M, Okai T: The role of p53 mutation in the carcinomas arising from endometriosis. Int J Gynecol Pathol; 2007 Jul;26(3):345-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To probe the mechanism of the development of ovarian cancer from endometriosis, which is a multistep process that involves the activation of oncogenes and inactivation of tumor suppressor genes, we evaluated p53 mutations in solitary endometriosis and endometriosis coexisting with ovarian clear cell carcinoma (OCCA) and ovarian endometrioid carcinoma (OEC).
  • We examined 7 cases of solitary ovarian endometriosis, 13 cases of OCCA, and 9 cases of OEC.
  • Cancer tissue specimens that also contained endometriosis without atypia were chosen.
  • We thought that some genetic alterations, which induce p53 mutations in endometriosis, may affect malignant transformation of endometriosis into OCCA.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Endometrioid / genetics. Endometriosis / genetics. Genes, p53. Ovarian Neoplasms / genetics. Point Mutation

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581423.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


58. Ardavanis A, Karamouzis MV, Alexopoulos A, Rigatos G: Simultaneous endometrioid ovarian and uterine carcinoma diagnosed after an in vitro fertilization procedure--case report and review of the literature. Eur J Gynaecol Oncol; 2005;26(6):654-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous endometrioid ovarian and uterine carcinoma diagnosed after an in vitro fertilization procedure--case report and review of the literature.
  • BACKGROUND: The presence of simultaneous carcinomas involving both the ovary and uterus is relatively uncommon, while the possible link between fertility drugs and carcinogenesis still remains controversial.
  • CASE: The case of a 40-year-old patient with simultaneous aggressive endometrioid carcinoma of the ovary and uterus a few months after the sixth attempt of in vitro fertilization is presented.
  • The patient had de novo lung disease at surgery and diffuse metastatic spread to adjacent bone, subcutaneous tissue and the central nervous system (CNS) soon after a spectacular response to the primary paclitaxel/carboplatinum chemotherapy and while on maintenance and second-line chemotherapy, respectively.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Fertilization in Vitro / adverse effects. Lung Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398231.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 16
  •  go-up   go-down


59. Chen S, Leitao MM, Tornos C, Soslow RA: Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol; 2005 Jul;18(7):903-11
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion.
  • Stage I, low-grade endometrioid and mucinous ovarian carcinomas have an excellent prognosis.
  • We investigated this by studying all FIGO stage I, grades 1 and 2 (of 3) endometrioid and mucinous ovarian carcinomas that were surgically staged at the Memorial Sloan-Kettering Cancer Center from 1980 to 2000.
  • Cases studied included 13 endometrioid ovarian carcinomas (stage IA, eight; stage IC, five) and six intestinal mucinous ovarian carcinomas (stage IA, three; stage IC, three).
  • Six tumors contained at least one focus of destructive stromal invasion (two endometrioid and four mucinous ovarian carcinomas).
  • Four additional cases showed a focus suspicious for but not diagnostic of destructive invasion ('indeterminate for destructive invasion') (two endometrioid and two mucinous ovarian carcinomas).
  • The size, number, and nuclear grade of destructive stromal invasion foci did not appear to have an impact on survival in this relatively limited number of patients.
  • Outcome data in patients with stage I, low-grade endometrioid and mucinous ovarian carcinomas without destructive stromal invasion indicate that these tumors have a very limited malignant potential.
  • The literature has not documented recurrences in this setting when the staging has been complete, the sampling adequate, and the cytologic features no more than grade 2, and metastasis to the ovary has been excluded.
  • In contrast, carcinomas harboring even limited foci of destructive stromal invasion, although frequently cured surgically, can pursue a malignant clinical course.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696121.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, Iasonos A, Goodglick L, Gordon LK, Braun J, Wadehra M: Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clin Cancer Res; 2010 Aug 1;16(15):3954-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.
  • PURPOSE: The tetraspan protein epithelial membrane protein-2 (EMP2) has been shown to regulate the surface display and signaling from select integrin pairs, and it was recently identified as a prognostic biomarker in human endometrial cancer.
  • In this study, we assessed the role of EMP2 in human ovarian cancer.
  • EXPERIMENTAL DESIGN: We examined the expression of EMP2 within a population of women with ovarian cancer using tissue microarray assay technology.
  • We evaluated the efficacy of EMP2-directed antibody therapy using a fully human recombinant bivalent antibody fragment (diabody) in vitro and ovarian cancer xenograft models in vivo.
  • RESULTS: EMP2 was found to be highly expressed in >70% of serous and endometrioid ovarian tumors compared with nonmalignant ovarian epithelium using a human ovarian cancer tissue microarray.
  • Using anti-EMP2 diabody, we evaluated the in vitro response of nine human ovarian cancer cell lines with detectable EMP2 expression.
  • Treatment of human ovarian cancer cell lines with anti-EMP2 diabodies induced cell death and retarded cell growth, and these response rates correlated with cellular EMP2 expression.
  • We next assessed the effects of anti-EMP2 diabodies in mice bearing xenografts from the ovarian endometrioid carcinoma cell line OVCAR5.
  • CONCLUSIONS: These findings indicate that EMP2 is expressed in the majority of ovarian tumors and may be a feasible target in vivo.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] FASEB J. 2004 Jan;18(1):206-8 [14597555.001]
  • [Cites] Clin Immunol. 2003 May;107(2):129-36 [12763482.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2073-83 [14978215.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jun;53(6):497-509 [14648071.001]
  • [Cites] Protein Eng Des Sel. 2004 Apr;17(4):315-23 [15187222.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Sep;31(3):309-16 [15205179.001]
  • [Cites] J Biopharm Stat. 2004 Aug;14(3):671-85 [15468758.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Nature. 1982 Jan 14;295(5845):116-9 [6173755.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1201-9 [15555554.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1032-42 [15564135.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 7;326(1):218-27 [15567174.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Blood. 2005 Jan 15;105(2):562-6 [15374889.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):131-41 [15942652.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jul 15;239(1-2):15-26 [15955618.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1605-16 [16227411.001]
  • [Cites] Dev Biol. 2005 Nov 15;287(2):336-45 [16216233.001]
  • [Cites] Dev Biol. 2006 Apr 15;292(2):430-41 [16487956.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):90-8 [16736513.001]
  • [Cites] Hum Pathol. 2006 Dec;37(12):1583-91 [16949910.001]
  • [Cites] Radiol Clin North Am. 2007 Jan;45(1):149-66 [17157627.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2007 Jul;16(4):353-8 [17565278.001]
  • [Cites] Immunol Res. 2007;39(1-3):271-8 [17917071.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6056-63 [17947468.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10484-90 [17974992.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):351-6 [18395030.001]
  • [Cites] Reprod Biol Endocrinol. 2008;6:15 [18400107.001]
  • [Cites] Ann Oncol. 2008 Sep;19 Suppl 7:vii61-6 [18790981.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7367-77 [19010852.001]
  • [Cites] Methods Mol Biol. 2009;472:413-37 [19107446.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2009 Jan;50(1):462-9 [18469192.001]
  • [Cites] Nat Rev Drug Discov. 2008 Sep;7(9):747-58 [18758472.001]
  • [Cites] FEMS Immunol Med Microbiol. 2009 Mar;55(2):240-9 [19159428.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1619-28 [19349354.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3890-5 [11389031.001]
  • [Cites] Cancer Gene Ther. 2001 Aug;8(8):555-65 [11571533.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41094-100 [12189152.001]
  • [Cites] Exp Mol Pathol. 2003 Apr;74(2):106-12 [12710941.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • (PMID = 20670949.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA016042; United States / NCI NIH HHS / CA / U24 CA086366; United States / NICHD NIH HHS / HD / R03 HD048540; United States / NCI NIH HHS / CA / R21 CA131756; United States / NCI NIH HHS / CA / P30 CA016042; United States / NCI NIH HHS / CA / NCI CA-86366; United States / NCI NIH HHS / CA / U54 CA119367; United States / NCI NIH HHS / CA / R21 CA131756-01A1; United States / NCI NIH HHS / CA / CA131756-01A1; United States / NICHD NIH HHS / HD / HD48540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EMP2 protein, human; 0 / Immunoglobulin Fragments; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ NIHMS211285; NLM/ PMC2913478
  •  go-up   go-down


61. Gregory-Bass RC, Olatinwo M, Xu W, Matthews R, Stiles JK, Thomas K, Liu D, Tsang B, Thompson WE: Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer; 2008 May 1;122(9):1923-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis.
  • Current approaches to the treatment of ovarian cancer are limited because of the development of resistance to chemotherapy.
  • Our study was designed to determine the role of Phb1 in regulating cellular growth and apoptosis in ovarian cancer cells.
  • Our results showed that Phb1 content is differentially overexpressed in papillary serous ovarian carcinoma and endometrioid ovarian adenocarcinoma when compared to normal ovarian epithelium and was inversely related to Ki67 expression.
  • Immunofluorescence microscopy and Western analyses revealed that Phb1 is primarily associated with the mitochondria in ovarian cancer cells.
  • Over-expression of Phb1 by adenoviral Phb1 infection resulted in an increase in the percentage of ovarian cancer cells accumulating at G0/G1 phase of the cell cycle.
  • Treatment of ovarian cancer cells with staurosporine (STS) induced apoptosis in a time-dependent manner.
  • In contrast, silencing of Phb1 expression by adenoviral small interfering RNA (siRNA) sensitized ovarian cancer cells to STS-induce apoptosis.
  • Taken together, these results suggest that Phb1 induces block at G0/G1 phase of the cell cycle and promotes survival of cancer cells.
  • Furthermore, silencing of the Phb1 gene expression may prove to be a valuable therapeutic approach for chemoresistant ovarian cancer by increasing sensitivity of cancer cells to apoptosis.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] EMBO J. 2000 Jun 1;19(11):2444-51 [10835343.001]
  • [Cites] Exp Gerontol. 1996 Jan-Apr;31(1-2):245-52 [8706794.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1699-706 [11245486.001]
  • [Cites] Exp Cell Res. 2001 May 1;265(2):262-73 [11302691.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):4076-85 [11517187.001]
  • [Cites] Mech Ageing Dev. 2002 Feb;123(4):287-95 [11744041.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4539-48 [12085232.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44870-6 [12244097.001]
  • [Cites] Exp Cell Res. 2003 Feb 15;283(2):135-45 [12581734.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1496-505 [12639934.001]
  • [Cites] Cell Death Differ. 2003 Aug;10(8):870-80 [12867994.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):32091-9 [12794069.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2996-3004 [14968116.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2293-303 [15141164.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):282-90 [15028627.001]
  • [Cites] J Reprod Fertil. 1997 Mar;109(2):337-48 [9155744.001]
  • [Cites] Mol Endocrinol. 1999 Aug;13(8):1364-72 [10446909.001]
  • [Cites] Anat Rec. 1999 Sep 1;256(1):40-8 [10456984.001]
  • [Cites] Mol Biol Cell. 2005 Jan;16(1):248-59 [15525670.001]
  • [Cites] Trends Mol Med. 2005 Apr;11(4):192-7 [15823758.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):837-43 [16041367.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6325-32 [16144937.001]
  • [Cites] Curr Cancer Drug Targets. 2006 May;6(3):207-27 [16712458.001]
  • [Cites] J Biol Chem. 2006 Nov 24;281(47):36401-10 [17008324.001]
  • [Cites] Endocrinology. 2007 Jan;148(1):206-17 [17038561.001]
  • [Cites] Oncogene. 2007 Mar 15;26(12):1757-68 [16964284.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):815-9 [17429401.001]
  • [Cites] Front Biosci. 2007;12:3628-39 [17485326.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19426-41 [17493932.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:66 [14609433.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3276-87 [15378696.001]
  • [Cites] Cell. 1986 Dec 5;47(5):767-76 [3779841.001]
  • [Cites] Trends Genet. 1993 Jan;9(1):22-6 [8434413.001]
  • [Cites] J Cell Physiol. 1993 Nov;157(2):289-95 [8227162.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):201-7 [8062216.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37101-9 [10958795.001]
  • (PMID = 18183577.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / 1 C06 RR18386; United States / NCRR NIH HHS / RR / G12 RR003034; United States / NCRR NIH HHS / RR / C06 RR018386; United States / NICHD NIH HHS / HD / R01 HD057235; United States / FIC NIH HHS / TW / R21 TW006804-02S1; United States / NCRR NIH HHS / RR / RR03034; United States / NCATS NIH HHS / TR / UL1 TR000454; United States / FIC NIH HHS / TW / R21 TW006804-01; United States / NICHD NIH HHS / HD / U54 HD041749; United States / NICHD NIH HHS / HD / U54 HD041749-01; United States / NICHD NIH HHS / HD / U54 HD41749; United States / FIC NIH HHS / TW / R21 TW006804; United States / FIC NIH HHS / TW / R21 TW006804-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Ki-67 Antigen; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; 0 / Repressor Proteins; 0 / prohibitin; EC 3.4.22.- / Caspase 3; H88EPA0A3N / Staurosporine
  • [Other-IDs] NLM/ NIHMS350695; NLM/ PMC3272361
  •  go-up   go-down


62. Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H: Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. Cancer; 2008 May 15;112(10):2211-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
  • BACKGROUND: Clinicopathological features and outcome of women with endometrioid and serous ovarian adenocarcinoma were compared.
  • METHODS: Between 1984 and 2004, baseline and follow-up data were prospectively recorded on 1545 patients with ovarian cancer.
  • Of these, 270 had pure endometrioid tumors; 659 had pure serous adenocarcinoma of the ovary.
  • RESULTS: Median age of diagnosis for patients with endometrioid tumors was younger than those with serous adenocarcinoma of the ovary (60 years vs 62 years; P = .013).
  • More endometrioid tumors were optimally debulked overall (71% vs 45%; P < .001), but there was no difference according to stage.
  • Objective and CA125 PBC response rates were not significantly different, but median PFS was better for patients with endometrioid tumors (24 months vs 13 months; P < .0001) as was overall median survival (48 months vs 22 months; P < .0001).
  • Patients with concurrent endometrioid ovarian and endometrial malignancies had a survival advantage compared with those with ovarian malignancies alone.
  • CONCLUSIONS: Despite similar PBC response rates, endometrioid histology is associated with better survival compared with serous adenocarcinoma of the ovary, even with stage III or poorly differentiated tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology


63. Chiang YC, Chen CA, Huang CY, Hsieh CY, Cheng WF: Synchronous primary cancers of the endometrium and ovary. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):159-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary cancers of the endometrium and ovary.
  • Simultaneous detection of malignancy in the endometrium and ovary represents an uncommon event.
  • The histologic determination was followed by the World Health Organization Committee classification, and cancer stage was based on the staging system of the FIGO.
  • The incidence of synchronous primary endometrial and ovarian cancers was 3.3% in patients with endometrial cancer and 2.7% in patients with ovarian cancer.
  • However, the impact of adjuvant therapy on survival did not reach statistic significance (P= 0.15 for chemotherapy; P= 0.69 for radiotherapy).
  • We conclude that the majority of the patients belonged to concordant endometrioid histology in endometrium and ovary, and it tends to be early stage and low grade with favorable prognosis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma, Clear Cell / secondary. Adult. Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / secondary. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506847.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res; 2005 Sep 15;11(18):6422-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
  • PURPOSE: The presence of similar histologic subtypes of epithelial ovarian and endometrial cancers has long been noted, although the relevance of this finding to pathogenesis and clinical management is unclear.
  • Despite similar clinical characteristics, histologic subtypes of cancers of the ovary and endometrium are treated according to organ of origin.
  • This study compares the gene expression profiles of analogous histologic subtypes of cancers of the ovary and endometrium using the same genomic platform to determine the similarities and differences between these tumors.
  • EXPERIMENTAL DESIGN: Gene expression profiles of 75 cancers (endometrioid, serous, and clear cell) of the ovary and endometrium, five renal clear cell cancers, and seven normal epithelial brushings were determined using a 11,000-element cDNA array.
  • RESULTS: Comparison across endometrial and ovarian cancers and serous and endometrioid tumors showed expression patterns reflecting their organ of origin.
  • A set of 43 genes was common to comparisons of each of the three histologic subtypes of ovarian cancer with normal ovarian surface epithelium.
  • CONCLUSIONS: The comparison of the gene expression profiles of endometrioid and serous subtypes of ovarian and endometrial cancer are largely unique to the combination of a particular subtype in a specific organ.
  • In contrast, clear cell cancers show a remarkable similarity in gene expression profiles across organs (including kidney) and could not be statistically distinguished.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Endometrioid / genetics. Cystadenocarcinoma, Serous / genetics. Endometrial Neoplasms / genetics. Gene Expression Profiling. Ovarian Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Cluster Analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kidney Neoplasms / genetics. Kidney Neoplasms / metabolism. Oligonucleotide Array Sequence Analysis / methods. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166416.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


65. Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A, Shroyer KR: B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol; 2007 Jul;106(1):119-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.
  • Previous studies have shown that B7-H4 is highly expressed in endometrioid ovarian cancers with relatively low levels of expression in normal ovary which was confirmed by Western blot.
  • The present study was designed to localize B7-H4 expression by immunohistochemistry (IHC) in normal endometrium, endometrial hyperplasia and uterine endometrioid adenocarcinoma.
  • RESULTS: The proportion and intensity of B7-H4 staining were increased in the progression from normal, hyperplastic and malignant endometrial glandular mucosa.
  • B7-H4 showed a predominantly apical membranous staining (pattern 1) in normal and hyperplastic endometrial epithelium but showed intense circumferential membranous and cytoplasmic staining (pattern 2) in a majority of endometrioid carcinoma cases (p=0.018).
  • CONCLUSIONS: B7-H4 is overexpressed in hyperplastic and malignant endometrial epithelium and is correlated with the number T cells associated with the tumor.
  • [MeSH-major] Antigens, CD80 / immunology. Carcinoma, Endometrioid / immunology. Lymphocytes, Tumor-Infiltrating / immunology. Ovarian Neoplasms / immunology. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509674.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


66. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • METHODS: The clinical data of 43 patients with synchronous primary cancers of the endometrium and ovary were retrospectively reviewed.
  • RESULTS: The median age at diagnosis was 49 years (range, 28-73 years).
  • FIGO stages of endometrial carcinomas: IA 18 cases, IB 20 cases, IC 2 cases, IIA 3 cases; Stages of ovarian carcinomas: IA 19 cases, IB 4 cases, IC 7 cases, II 4 cases, III C 9 cases.
  • Twenty-four patients (55.8%) were in stage I both endometrial and ovarian carcinomas.
  • Thirty-eight of the 43 patients (88.4%) had a pathologically proven endometrial adenocarcinoma.
  • The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%).
  • The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%).
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


67. Lou HM, Lou HK, Wu MJ: [Synchronous primary cancer of the endometrium and ovary]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):617-20
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancer of the endometrium and ovary].
  • To investigate the clinical and pathological characteristics, treatment, and The data of 12 patients prognosis of synchronous primary cancer of the endometrium and ovary.
  • Methods with synchronous primary cancer of the endometrium and ovary were retrospectively reviewed .
  • Results Eight patients had the same histological type of endometrioid carcinoma in both uterus and ovary, 4 patients had different histological types in uterus and ovary.
  • Synchronous primary cancer of the endometrium and ovary was difficult to be dignosed preoperatively.
  • All ovarian tumors were small with an average diameter of 7 cm.
  • endometrioid carcinomas was the main pathologic type (66.7%).
  • CONCLUSION: Synchronous primary endometrium and ovary cancer is a specific kind of tumor different from either the primary endometrium carcinoma or ovary carcinoma, and usually can be detected in early stage with a good prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236559.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol
  •  go-up   go-down


68. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol; 2009 Jun;22(6):824-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 expression in clear cell adenocarcinoma of the ovary.
  • Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor.
  • To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases.
  • A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied.
  • Glypican-3 expression was observed in 44% of clear cell adenocarcinomas, whereas it was rarely observed in other histological subtypes: mucinous (4%), endometrioid (5%), and serous (11%; P<0.0001).
  • All six ovarian yolk sac tumors showed diffuse immunoreactivity for glypican-3.
  • In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate.
  • However, glypican-3 expression was significantly associated with poor overall survival in stage III/IV clear cell adenocarcinoma cases.
  • Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Glypicans / biosynthesis. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329941.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


69. Silva EG, Young RH: Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol; 2007 Aug;31(8):1203-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type.
  • The presence of clear cells in genital tract neoplasms often reflexly prompts the diagnosis of a clear cell tumor but clear cells may be seen in many other neoplasms.
  • In one such, those of endometrioid type, they are well known and generally readily characterized when they have the secretory pattern that recapitulates the well-known morphology of early secretory endometrium.
  • In this report, we describe various clear cell morphologies, some possibly related to the secretory variant, but others not, and all potentially the source of significant diagnostic difficulty.
  • We reviewed 21 endometrioid tumors that occurred in patients from 27 to 88 (median 64) years.
  • One tumor formed a cystic mass in the pelvis, 1 tumor involved the right fallopian tube, 1 the endometrium, and 18 the ovary.
  • All the neoplasms had the typical architecture of endometrioid tumors but differed markedly in their cytoplasmic features.
  • Tubulocystic, solid, and papillary patterns of clear cell carcinoma were absent.
  • Although a few cases had a focal slight resemblance to secretory endometrioid carcinoma most did not and the orderly morphology of classic secretory carcinoma was noteworthy for its absence.
  • The distinction from clear cell carcinoma depends on awareness of this unusual variant of endometrioid neoplasia and a lack of the distinctive patterns of clear cell carcinoma; at this time, special studies, including immunohistochemistry, do not aid significantly although certainly negative reactions, such as for thyroglobulin protein (arguing against clear cell struma ovarii) may play a role in some differential diagnostic considerations.
  • There are prognostic and therapeutic implications in the distinction with clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2007 Oct;31(10):1628
  • (PMID = 17667544.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Stewart CJ, Brennan BA, Hammond IG, Leung YC, McCartney AJ, Ruba S: Intraoperative assessment of clear cell carcinoma of the ovary. Int J Gynecol Pathol; 2008 Oct;27(4):475-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative assessment of clear cell carcinoma of the ovary.
  • Frozen section is a reliable technique in gynecologic pathology and is widely used to guide intraoperative management in patients presenting with ovarian masses.
  • However, there are limited data regarding the diagnostic accuracy of frozen section in specific subtypes of ovarian neoplasia.
  • Our impression that primary clear cell carcinoma (CCC) causes disproportionate diagnostic difficulty led us to review the intraoperative and final histopathologic reports from a consecutive series of 44 CCC that were subject to frozen-section assessment and to compare the results with a similar number of primary serous and endometrioid carcinomas.
  • Review of the diagnostic reports showed that CCC was less frequently specifically identified than serous or endometrioid carcinomas on frozen section (44% cases compared with 55% and 65%, respectively), although the differences were not statistically significant.
  • Difficulties in distinguishing primary ovarian carcinoma from tumors metastatic to the ovary occurred in a minority of cases of all histologic subtypes, but was slightly more frequent in CCC.
  • Review of the frozen-section slides from the CCC with discrepant intraoperative diagnoses showed features suggestive or indicative of the correct diagnosis in 7 (39%) of 18 cases.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / pathology. Female. Frozen Sections. Histocytochemistry. Humans. Intraoperative Care / methods. Pathology, Surgical. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753976.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Maeda D, Takazawa Y, Oda K, Nakagawa S, Fukayama M: Glomus tumor of the ovary: a case report. Int J Surg Pathol; 2010 Dec;18(6):557-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glomus tumor of the ovary: a case report.
  • A 55-year-old woman underwent a total hysterectomy, bilateral salpingo-oophorectomy, partial omentectomy, and lymphadenectomy for endometrial cancer.
  • Histologically, the cancer was endometrioid adenocarcinoma grade 1, which invaded the myometrium.
  • However, histological examination revealed a small tumor, 1 mm in size, in the medulla of the right ovary.
  • The ovarian tumor was composed of uniform epithelioid cells that grew in nests.
  • Immunohistochemically, the ovarian tumor was positive for smooth muscle actin and vimentin but negative for desmin and CD34.
  • Based on these findings, the authors made the diagnosis of ovarian glomus tumor.
  • Although an ovarian glomus tumor is extremely rare, the authors believe that it should be included in the differential diagnosis of ovarian mesenchymal tumors and sex cord tumors.
  • [MeSH-major] Glomus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20667926.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Terada T: Adenosquamous carcinoma of the ovary arising from endometriosis: two case reports. Cases J; 2009;2:6661

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the ovary arising from endometriosis: two case reports.
  • The author reports two cases of adenosquamous carcinoma arising from endometriosis of ovaries.
  • Both patients underwent hysterectomy and bilateral salpingo-oophorectomy for ovarian carcinomas.
  • Grossly, both ovarian tumors were located in the left ovaries, and were cystic tumors with mural tumors.
  • Both mural tumors were composed of grade I endometroid adenocarcinoma and squamous cell carcinoma.
  • A differentiation of endometrioid adenocarcinoma from the endometriosis were present in a few areas.
  • Likewise, a differentiation of squamous cell carcinoma from the endometriosis were recognized in several areas.
  • The pathologic diagnosis was adenosquamous carcinoma arising from endometriosis of the ovary in both cases, rather than endometrioid adenocarcinoma with malignant squamous differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Jul;42(1):326-9 [208753.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:11-7 [11093056.001]
  • [Cites] Clin Obstet Gynecol. 1966 Jun;9(2):384-411 [5330412.001]
  • [Cites] Gynecol Oncol. 1988 May;30(1):143-8 [3366390.001]
  • (PMID = 20184682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827079
  •  go-up   go-down


73. Pearce CL, Wu AH, Gayther SA, Bale AE, Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group, Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards R, Fredericksen ZS, Garcia-Closas M, Goode EL, Green AC, Hartmann LC, Hogdall E, Kjaer SK, Lissowska J, McGuire V, Modugno F, Moysich K, Ness RB, Ramus SJ, Risch HA, Sellers TA, Song H, Stram DO, Terry KL, Webb PM, Whiteman DC, Whittemore AS, Zheng W, Pharoah PD, Chenevix-Trench G, Pike MC, Schildkraut J, Berchuck A, Ovarian Cancer Association Consortium: Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer; 2008 Jan 29;98(2):282-8
Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.
  • There is evidence that progesterone plays a role in the aetiology of invasive epithelial ovarian cancer.
  • Previous studies have suggested that genetic variants in the progesterone receptor gene (PGR) may be associated with ovarian cancer risk, although results have been inconsistent.
  • We have established an international consortium to pool resources and data from many ovarian cancer case-control studies in an effort to identify variants that influence risk.
  • In this study, three PGR single nucleotide polymorphisms (SNPs), for which previous data have suggested they affect ovarian cancer risk, were examined.
  • A total of 4788 ovarian cancer cases and 7614 controls from 12 case-control studies were included in this analysis.
  • Unconditional logistic regression was used to model the association between each SNP and ovarian cancer risk and two-sided P-values are reported.
  • Overall, risk of ovarian cancer was not associated with any of the three variants studied.
  • However, in histopathological subtype analyses, we found a statistically significant association between risk of endometrioid ovarian cancer and the PROGINS allele (n=651, OR=1.17, 95% CI=1.01-1.36, P=0.036).
  • We also observed borderline evidence of an association between risk of endometrioid ovarian cancer and the +331C/T variant (n=725 cases; OR=0.80, 95% CI 0.62-1.04, P=0.100).
  • These data suggest that while these three variants in the PGR are not associated with ovarian cancer overall, the PROGINS variant may play a modest role in risk of endometrioid ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2001 May;22(5):717-21 [11323389.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):714-21 [11237375.001]
  • [Cites] Int J Cancer. 2001 Nov 20;95(6):394-7 [11668524.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):32-8 [11773280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12263-8 [12218173.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):300-6 [12432283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):42-6 [12540502.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):177-82 [12524541.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7 [12646513.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):378-81 [12893203.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Fertil Steril. 2004 Jul;82(1):186-95 [15237010.001]
  • [Cites] N Engl J Med. 1987 Mar 12;316(11):650-5 [3821795.001]
  • [Cites] Am J Obstet Gynecol. 1989 Jul;161(1):10-6 [2750791.001]
  • [Cites] EMBO J. 1990 May;9(5):1603-14 [2328727.001]
  • [Cites] Eur J Cancer. 1992;28A(11):1872-6 [1389530.001]
  • [Cites] Mol Endocrinol. 1993 Oct;7(10):1244-55 [8264658.001]
  • [Cites] Am J Epidemiol. 1994 Apr 1;139(7):654-61 [8166126.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):451-5 [7880723.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2743-5 [7796397.001]
  • [Cites] Br J Cancer. 1997;75(9):1398-9 [9155067.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2095-7 [9605750.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):277 [9683307.001]
  • [Cites] J Soc Gynecol Investig. 1998 Sep-Oct;5(5):271-6 [9773403.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86 [9839517.001]
  • [Cites] Cancer Causes Control. 1999 Oct;10(5):397-402 [10530609.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6340-7 [15579801.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7 [15598772.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 5;97(1):51-9 [15632380.001]
  • [Cites] Am J Epidemiol. 2005 Mar 1;161(5):442-51 [15718480.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):611-8 [15924337.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2536-43 [16284375.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2807-16 [16284991.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):287-95 [16360811.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1738-41 [16985038.001]
  • [Cites] Carcinogenesis. 2006 Nov;27(11):2235-42 [16774946.001]
  • [Cites] J Mol Endocrinol. 2007 Feb;38(1-2):331-50 [17293450.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3027-35 [17409409.001]
  • [Cites] BMC Cancer. 2007;7:60 [17411440.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):170-6 [17721999.001]
  • [Cites] Am J Epidemiol. 2000 Aug 1;152(3):233-41 [10933270.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1488-94 [11076658.001]
  • [Cites] Int J Cancer. 2001 Nov 20;95(6):370-4 [11668519.001]
  • (PMID = 18219286.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-6710; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / CA14089; United States / NCI NIH HHS / CA / 5R01-CA074850; United States / NCI NIH HHS / CA / R03-CA113148; United States / NCI NIH HHS / CA / R03 CA113148; United States / NCI NIH HHS / CA / R01 CA080742; United States / NCI NIH HHS / CA / R01 CA074850; United States / NCI NIH HHS / CA / CA71966; United States / NCI NIH HHS / CA / 5R01-CA080742; United States / NCI NIH HHS / CA / CA63464; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / P30 CA014089; United States / NCI NIH HHS / CA / CA17054; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / U01 CA063464; United States / NCI NIH HHS / CA / CA61132; United States / NCI NIH HHS / CA / R01 CA 61107; United States / NCI NIH HHS / CA / P01 CA017054
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2361465
  •  go-up   go-down


74. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • Microarray analysis revealed recently that hepatocyte nuclear factor-1beta (HNF-1beta) was significantly upregulated in clear cell carcinoma of the ovary.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • Early differentiation into the clear cell lineage takes place in ovarian endometriosis, not only in atypical endometriosis, but also in endometriosis with degenerative and regenerative changes, and this is probably responsible for the frequent occurrence of clear cell carcinoma in ovarian endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Ovarian Cysts / metabolism. Ovarian Cysts / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


75. Chew I, Post MD, Carinelli SG, Campbell S, Di Y, Soslow RA, Oliva E: p16 expression in squamous and trophoblastic lesions of the upper female genital tract. Int J Gynecol Pathol; 2010 Nov;29(6):513-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aims to further characterize p16 expression in trophoblastic lesions and squamous lesions of the upper female genital tract, as little data exists. p16 immunostaining was performed on sections from ichthyosis uteri (1), primary uterine corpus squamous cell carcinoma (UCSCC) (2), primary ovarian SCC (OSCC) (5; 2 associated with a dermoid cyst), endometrial endometrioid adenocarcinoma with extensive squamous differentiation (EC-SD) (5), ovarian endometrioid adenocarcinoma with extensive squamous differentiation (OC-SD) (4), placental site nodule (5), and placental site trophoblastic tumor (PSTT) (6).
  • Thus, when considering the differential diagnosis of cervical SCC and trophoblastic lesions, only strong diffuse p16 staining should be considered helpful.
  • [MeSH-major] Genital Neoplasms, Female / diagnosis. Neoplasm Proteins. Neoplasms, Squamous Cell / diagnosis. Trophoblastic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881863.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P16 protein, human
  •  go-up   go-down


76. Mukonoweshuro P, Oriowolo A: Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma. Gynecol Oncol; 2005 Oct;99(1):222-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma.
  • BACKGROUND: Stromal osseous metaplasia is a rare and curious finding in tumors of the ovary.
  • CASE REPORT: The patient, a 66-year-old P3 G3 white female, had a past history of stage 1c left ovarian, well-differentiated endometrioid adenocarcinoma removed in 1981.
  • The tumor recurred 21 years later with prominent stromal osseous metaplasia that had not been present in the primary.
  • DISCUSSION: The pathogenesis of osseous metaplasia in epithelial tumors of the ovary is unclear; however, it is probable that a metaplastic process involving multipotential stromal stem cells results in bone formation.
  • CONCLUSION: Benign osseous metaplasia in ovarian tumors is rare and its histogenesis remains unclear.
  • As far as we know, this process does not appear to have any prognostic or pathological significance.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023183.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Fanghong Li, Szallasi A, Young RH: Wolffian tumor of the ovary with a prominent spindle cell component: report of a case with brief discussion of unusual problems in differential diagnosis, and literature review. Int J Surg Pathol; 2008 Apr;16(2):222-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wolffian tumor of the ovary with a prominent spindle cell component: report of a case with brief discussion of unusual problems in differential diagnosis, and literature review.
  • An 87-year-old woman underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometrioid adenocarcinoma.
  • At operation, a 4.5-cm partially solid and partially cystic right ovarian mass was identified.
  • Extensive sampling of the ovarian mass revealed a focus with the classic sieve-like pattern of a Wolffian adnexal tumor that merged with the fibroma-like appearance.
  • The uterus showed well-differentiated, superficially invasive endometrioid adenocarcinoma arising in a background of atypical complex hyperplasia.
  • Given the recent reports implying a therapeutic value for Gleevec (Novartis, Stein, Switzerland) (STI-571) in the treatment of Wolffian tumor of the ovary, paraffin immunostain for CD117 (c-kit) was performed that yielded negative results.
  • This case demonstrates the heterogeneity of Wolffian tumor of the ovary and shows how crucial sampling is in arriving at the correct diagnosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Fibroma / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Wolffian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417686.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Young RH: From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol; 2007 May;14(3):149-77
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
  • This is the second of a two-part consideration of metastatic tumors to the ovary.
  • The first tumor discussed is gastric carcinoma of intestinal-type whose ovarian manifestations have been the subject of a recent paper which emphasized its differences from the Krukenberg tumor.
  • Coverage of intestinal adenocarcinoma emphasizes the landmark 1987 paper of RH Lash and WR Hart.
  • The section on pancreatic neoplasms reemphasizes the problems caused by metastatic ductal carcinoma, considered primarily in Part I, and discusses less common issues such as spread of neuroendocrine and acinar cell carcinomas.
  • The limited information on spread of tumors of the gallbladder and extrahepatic bile ducts is then reviewed before more detailed consideration of hepatic neoplasms, prompted by recent contributions on hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the latter based on significant experience with this problem in Thailand.
  • The section on appendiceal neoplasms highlights ovarian spread of diverse tumors ranging from typical intestinal-type adenocarcinoma to signet-ring cell carcinomas with various patterns which in the ovary may prompt diagnoses such as a goblet cell (mucinous) carcinoid tumor, but whose ovarian features place them in the category of a Krukenberg tumor.
  • The diverse problems in differential diagnosis of carcinoid tumor (provoked by nested, acinar, and other patterns, including folliclelike spaces) are then reviewed.
  • The section on breast cancer emphasizes that, although usually a manifestation of late stage disease and often not bulky in the ovaries, metastatic breast cancer may form large masses which can represent the clinical presentation.
  • That patients with breast cancer have an increased risk of primary ovarian cancer and that the latter is more common than secondary spread of breast cancer is noted.
  • The section on lung tumors largely reflects information in a recent paper that small cell carcinoma and adenocarcinoma are the lung cancers that spread to the ovary most commonly.
  • The extremely broad differential diagnosis posed by metastatic malignant melanoma ranging from that of an oxyphilic tumor, to a small cell tumor, to a follicle-forming neoplasm, is then considered.
  • The sections on renal cell carcinoma and other urinary tract neoplasms emphasize the differential diagnosis of metastatic clear cell carcinoma and primary clear cell carcinoma, an issue usually resolvable by an awareness of the various features of the ovarian variant, rarely or never seen in the renal variant.
  • The endometrial stromal tumors are problematic largely because the history of a primary tumor may be remote, in the ovaries the typical growth and vascular pattern of endometrial stromal neoplasms is not always conspicuous, and some endometrial stromal sarcomas in the ovary show sex cordlike patterns of growth.
  • Recent information has indicated that gastrointestinal stromal tumors may rarely have significant ovarian manifestations and if the primary neoplasm is overlooked, the ovarian tumor may be misdiagnosed, usually as an ovarian fibromatous tumor, but potentially as another primary neoplasm.
  • The sections on ovarian spread of uterine carcinomas emphasize the problems owing to cervical adenocarcinomas, which have a greater tendency to involve the ovaries than squamous cell carcinomas and can simulate primary mucinous or endometrioid cancers.
  • The final neoplasms considered are malignant mesothelioma and the desmoplastic small round cell tumor.
  • The microscopic features of malignant mesothelioma are so different from those of primary ovarian carcinoma in most instances that the diagnosis should be readily established on routine microscopic evaluation.
  • The differential diagnosis of the desmoplastic small round cell tumor is more complex because of the greater overlap with the many other small cell malignant tumors that may involve the ovaries primarily or secondarily.
  • However, as pointed out in brief concluding remarks, despite the aid of that modality, as in surgical pathology overall, careful consideration of the clinical background, distribution of disease, gross characteristics and spectrum of routine microscopic findings, will lead to the correct diagnosis in the majority of cases and at the very least lead to formulation of a considered differential diagnosis such that use of special techniques may be judicious and those results placed in context of the time-honored clinical and pathologic features.
  • [MeSH-major] Carcinoma / secondary. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Female. History, 19th Century. History, 20th Century. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452813.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


79. Güzin K, Tekcan C, Naki MM, Kayataş S, Zemheri E, Kanadikirik F, Berkman S: Synchronous primary cancers of the endometrium and ovary: a case report. Eur J Gynaecol Oncol; 2006;27(4):425-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary cancers of the endometrium and ovary: a case report.
  • Synchronous primary cancers of the endometrium and ovary are found in 5% of women with endometrial cancer and 10% of women with ovarian cancer.
  • She did not define abnormal uterine bleeding.
  • Screening ultrasound revealed a papillary containing structure, irregular, cystic 16 x 15 x 10 cm right ovarian mass.
  • Preoperative endometrial biopsy revealed endometrioid adenocarcinoma.
  • Intraoperative and histological examinations showed Stage IIIC papillary serous carcinoma and stage IC endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasms, Multiple Primary / etiology. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009644.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


80. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Papathanasiou K, Tolikas A, Dovas D, Kostopoulou E, Fragkedakis N, Tzafettas J: Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1191-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology.
  • A case of a mucinous adenocarcinoma of the ovary with a synchronous endometroid tumor of the endometrium with focal features of undifferentiated carcinoma and deep myometrial invasion is reported.
  • A review of the literature revealed that our case is interesting in view of the fact that simultaneous presentation of primary ovarian and endometrial neoplasms is rare and usually related to low-stage ovarian lesions and well-differentiated and superficial endometrial carcinomas in contrast to our case with the focal features of undifferentiated carcinoma and the deep myometrial invasion.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343211.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Natee J, Kietpeerakool C, Srisomboon J, Khunamornpong S, Suprasert P, Phongnarisorn C, Cheewakriangkrai C, Charoenkwan K, Siriaree S, Pantusart A: Clinicopathologic analysis of women with synchronous primary carcinomas of the endometrium and ovary: 10- year experience from Chiang Mai University Hospital. Asian Pac J Cancer Prev; 2006 Apr-Jun;7(2):234-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of women with synchronous primary carcinomas of the endometrium and ovary: 10- year experience from Chiang Mai University Hospital.
  • The aim of this study was to analyze the clinicopathologic features and survival outcomes of women with synchronous primary carcinomas of the endometrium and ovary that were treated at Chiang Mai University Hospital between January 1995 and December 2004.
  • Median age at diagnosis was 49 years (range: 34-60 years).
  • Twenty-seven (62.8%, 95%CI= 46.7-77.0%) women had concordant endometrioid carcinomas of the endometrium and ovary.
  • There was no significant difference in survival outcomes among the women who had endometrioid/endometrioid histology and those who had other histological subtypes (P=0.674).
  • In conclusion, synchronous primary carcinomas of the endometrium and ovary, although uncommon, should be considered in differential diagnosis in premenopausal women presenting with abnormal uterine bleeding and ovarian tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16839215.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


83. Saglam A, Bozdag G, Kuzey GM, Kuçukali T, Ayhan A: Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube. Arch Gynecol Obstet; 2008 Jun;277(6):557-62
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube.
  • OBJECTIVE: To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube.
  • The frozen section of the mass on the right adnex revealed malign mucinous carcinoma of the ovary.
  • As usual, optimal debulking was performed as initial surgical staging procedure of ovarian cancer.
  • The microscopic examination of the right ovary revealed a typical mucinous cystadenocarcinoma.
  • Furthermore, the focal endometrial irregularity at the left uterine cornus turned out to be a well differentiated endometrial carcinoma of the endometrioid type with <1/3 myometrial invasion.
  • The pale infiltrative lesion in the cervix also turned out to be an adenocarcinoma of the endocervical type with deep stromal invasion and areas of diffuse glandular dysplasia and in-situ glandular neoplasia at the periphery.
  • Besides, several sections from the left fallopian tube uncovered diffuse dysplasia in the lining epithelium and a focus of adenocarcinoma with papillary and cribriform pattern.
  • In such cases, the validity of immunohistochemical and cloning studies are not clear.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066567.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Lewis MR, Deavers MT, Silva EG, Malpica A: Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol; 2006 Feb;30(2):177-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge.
  • Ovarian involvement by metastatic colorectal adenocarcinoma, although not an uncommon occurrence, remains a diagnostic challenge.
  • The gross and histologic features of such metastases overlap those of primary ovarian epithelial neoplasms such as endometrioid or mucinous adenocarcinoma.
  • The clinical and pathologic features of 86 cases of metastatic colorectal adenocarcinoma involving the ovary were reviewed.
  • In 23 cases, an ovarian mass was the first manifestation of the disease.
  • Ovarian involvement was bilateral in 49 cases and unilateral in 33 (including 20 cases in which the only involved ovary measured at least 10 cm in greatest dimension).
  • In general, the tumors had typical histologic features of metastatic colorectal adenocarcinoma, including a garland pattern and dirty necrosis.
  • In 23 cases, foci with a benign or low malignant potential appearance were seen.
  • In 9 of the cases, an ovarian primary was diagnosed or favored initially, and 5 of these cases were initially treated as ovarian primaries.
  • Metastatic colorectal adenocarcinoma should be considered in the differential diagnosis of an ovarian mass, even if the mass is large and unilateral or in a young patient, to secure proper treatment of these patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434891.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Abbott KL, Nairn AV, Hall EM, Horton MB, McDonald JF, Moremen KW, Dinulescu DM, Pierce M: Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Proteomics; 2008 Aug;8(16):3210-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer.
  • Epithelial ovarian cancer is the deadliest female reproductive tract malignancy in Western countries.
  • Less than 25% of cases are diagnosed when the cancer is confined, however, pointing to the critical need for early diagnostics for ovarian cancer.
  • Identifying the changes that occur in the glycome of ovarian cancer cells may provide an avenue to develop a new generation of potential biomarkers for early detection of this disease.
  • We performed a glycotranscriptomic analysis of endometrioid ovarian carcinoma using human tissue, as well as a newly developed mouse model that mimics this disease.
  • Our results show that the N-linked glycans expressed in both nondiseased mouse and human ovarian tissues are similar; moreover, malignant changes in the expression of N-linked glycans in both mouse and human endometrioid ovarian carcinoma are qualitatively similar.
  • This study provides evidence that glycotranscriptome analysis can be an important tool in identifying potential cancer biomarkers.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1982 Oct 10;257(19):11235-40 [7118881.001]
  • [Cites] J Biol Chem. 1982 Oct 10;257(19):11230-4 [7118880.001]
  • [Cites] J Biol Chem. 1987 Feb 5;262(4):1602-7 [3805046.001]
  • [Cites] Clin Chim Acta. 1989 Dec 15;185(3):325-32 [2482796.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):718-23 [1985789.001]
  • [Cites] Biochim Biophys Acta. 1991 Jan 29;1076(2):187-90 [1998719.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8754-8 [7568011.001]
  • [Cites] Glycobiology. 1996 Oct;6(7):691-4 [8953279.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19575-81 [9235963.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2881-7 [9661906.001]
  • [Cites] Glycoconj J. 1998 Oct;15(10):1033-7 [10211708.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):605-19 [16021566.001]
  • [Cites] Immunol Cell Biol. 2005 Aug;83(4):429-39 [16033539.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):631-9 [16112178.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] Exp Cell Res. 2006 Sep 10;312(15):2837-50 [16857188.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):692-7 [16793127.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):22150-62 [17537730.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4374-87 [17915907.001]
  • [Cites] Glycobiology. 2007 Dec;17(12):1344-56 [17884841.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):397-404 [18268124.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17298-313 [18411279.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):247-66 [10580143.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):567-76 [10675491.001]
  • [Cites] Biochim Biophys Acta. 2000 Feb 28;1495(3):297-307 [10699467.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):53-62 [12086888.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 19;1573(3):363-8 [12417419.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6837-45 [12460896.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):27059-67 [12732625.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28619-34 [12734200.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52412-24 [14561752.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Biochemistry. 1969 Jun;8(6):2518-24 [4307997.001]
  • [Cites] J Biol Chem. 1986 Aug 15;261(23):10772-7 [3015940.001]
  • (PMID = 18690643.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41RR018502; United States / NCI NIH HHS / CA / R01 CA064462; United States / NCRR NIH HHS / RR / P41 RR018502; United States / NCI NIH HHS / CA / UO/CA128454; United States / NCI NIH HHS / CA / U01 CA128454; United States / NCI NIH HHS / CA / R01CA064462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Lectins; 0 / Polysaccharides; EC 2.3.- / Acyltransferases; EC 2.3.1.22 / 2-acylglycerol O-acyltransferase; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.155 / alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase; EC 2.4.1.68 / Glycoprotein 6-alpha-L-fucosyltransferase
  • [Other-IDs] NLM/ NIHMS559841; NLM/ PMC3970323
  •  go-up   go-down


86. Tao X, Kavanagh JJ: Chemotherapy for gynecological malignancies in organ transplantation patients: report of two cases. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1376-80
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first case, a rare occurrence of simultaneous carcinomas of the uterine corpus and ovary, is the first such report in the English literature describing chemotherapy for concurrent serous papillary ovarian carcinoma and endometrioid endometrial carcinoma in a renal transplant patient.
  • The second case report, describing chemotherapy for cervical cancer following two organ transplantation, also rare, is the first such report in the English literature and the first report of cervical cancer after heart-kidney transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Heart Transplantation. Kidney Transplantation. Ovarian Neoplasms / drug therapy. Uterine Neoplasms / drug therapy


87. Sciallis AP, Aubry MC, Bell DA: Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case. Int J Gynecol Pathol; 2009 Sep;28(5):447-52
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case.
  • A patient with bilateral ovarian adenocarcinomas composed predominantly of ciliated cells incidentally found at autopsy is reported.
  • Although obviously malignant, a majority of the cells expressed well-differentiated cilia with terminal bar formation.
  • Although morphologically resembling an endometrioid-type neoplasm, immunohistochemical and molecular studies were more consistent with a serous phenotype, especially in light of its apparent origination from a serous adenofibroma.
  • [MeSH-major] Adenocarcinoma / pathology. Cilia / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696614.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Jin JS, Yao CW, Loh SH, Cheng MF, Hsieh DS, Bai CY: Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Gynecol Pathol; 2006 Apr;25(2):140-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
  • Ovary cancer invasion is responsible for both local tissue destruction and distant metastasis.
  • We hypothesized that EMMPRIN isoverexpressed in ovary tumors.
  • Immunohistochemical analysis of EMMPRIN was performed in tissue microarrays of ovary neoplasms including 84 cases of serous adenocarcinoma, 23 cases of mucinous adenocarcinoma, 10 cases of endometrioid adenocarcinoma, 12 cases of yolk sac tumor, 12 cases of clear cell carcinoma, 8 cases of dysgerminoma, 8 cases of granulosa cell tumor, 6 cases of transitional cell carcinoma, and 6 cases of Brenner tumor.
  • All malignant ovary tumors showed significant immunohistochemical expression of EMMPRIN.
  • The EMMPRIN scores in malignant ovary tumors were significantly higher than their nontumor counterparts (313+/-28 for serous adenocarcinoma; 308+/-25 for mucinous adenocarcinoma; 187+/-19 for endometrioid adenocarcinoma; 265+/-23 for yolk sac tumors; 87+/-13 for clear cellcarcinoma; 126+/-15 for dysgerminoma; 243+/-26 for granulosa cell tumor; 87+/-16 for transitional cell carcinoma).
  • Our findings show for the first time that EMMPRIN is overexpressed in all malignant ovary tumors.
  • [MeSH-major] Antigens, CD147 / analysis. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / pathology. Tissue Array Analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Brenner Tumor / chemistry. Brenner Tumor / genetics. Brenner Tumor / pathology. Carcinoma, Transitional Cell / chemistry. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Dysgerminoma / chemistry. Dysgerminoma / genetics. Dysgerminoma / pathology. Endodermal Sinus Tumor / chemistry. Endodermal Sinus Tumor / genetics. Endodermal Sinus Tumor / pathology. Female. Granulosa Cell Tumor / chemistry. Granulosa Cell Tumor / genetics. Granulosa Cell Tumor / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633062.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 136894-56-9 / Antigens, CD147
  •  go-up   go-down


89. Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H: Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep; 2009 Aug;22(2):233-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review).
  • Epithelial ovarian cancer (EOC) is the leading cause of death in women with gynecological malignancies.
  • Among EOC, clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC) differ from the other histological types with respect to their clinical characteristics and carcinogenesis.
  • The present article reviews the English language literature for biological, pathogenetic and pathophysiological studies on endometriosis-associated CCC of the ovary.
  • Retrograde menstruation or ovarian hemorrhage carries highly pro-oxidant factors, such as heme and iron, into the peritoneal cavity or ovarian endometrioma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578761.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / FBXO5 protein, human; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  • [Number-of-references] 56
  •  go-up   go-down


90. Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT: Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A; 2006 Nov 14;103(46):17426-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
  • Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents.
  • Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with doxorubicin, paclitaxel, or cisplatin as agents in clinical use.
  • MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line.
  • A paclitaxel-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro.
  • Additivity, synergy, or competition was observed with MIS and rapamycin, AzadC, doxorubicin, cisplatin, and paclitaxel, suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Biomed Sci. 1994 Jun;51(2):147-57 [8049612.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):850-6 [9041185.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • [Cites] Am J Anat. 1977 Jul;149(3):353-75 [879051.001]
  • [Cites] J Surg Res. 1977 Aug;23(2):141-8 [886843.001]
  • [Cites] Science. 1979 Aug 31;205(4409):913-5 [472712.001]
  • [Cites] Am J Anat. 1979 Oct;156(2):265-84 [506954.001]
  • [Cites] Dev Biol. 1982 Jul;92(1):16-26 [7106377.001]
  • [Cites] Dev Biol. 1982 Jul;92(1):27-40 [7106385.001]
  • [Cites] Cancer Res. 1985 Oct;45(10):4970-9 [3861241.001]
  • [Cites] Cell. 1986 Jun 6;45(5):685-98 [3754790.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2101-6 [2009529.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):466-71 [1732773.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1182-6 [1531323.001]
  • [Cites] Protein Expr Purif. 1992 Jun;3(3):236-45 [1392620.001]
  • [Cites] Development. 1994 Jan;120(1):189-97 [8119126.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1211-6 [7566983.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):160-5 [8536608.001]
  • [Cites] Cell. 1996 Aug 9;86(3):435-44 [8756725.001]
  • [Cites] N Engl J Med. 1997 May 22;336(21):1480-6 [9154766.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):51-5 [10094880.001]
  • [Cites] Development. 1999 Jun;126(11):2551-61 [10226013.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4732-8 [10499532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6 [15618407.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13831-8 [10570158.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3488-99 [10589763.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27973-8 [10854429.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28371-9 [10874041.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37101-9 [10958795.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3214-9 [11248058.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3393-7 [11248089.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):936-45 [11376112.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):946-59 [11376113.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26799-806 [11356848.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):239-44 [11773638.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98 [11820299.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2640-6 [12171896.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):408-10 [12368913.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1389-97 [12649204.001]
  • [Cites] Mol Cell Endocrinol. 2003 Dec 15;211(1-2):43-9 [14656475.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51703-12 [14532292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6 [14671316.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:619-31 [14766396.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):759-67 [14999786.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):1-8 [15385103.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6779-88 [15501954.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3948-56 [15883410.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7889-96 [16204015.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16421-5 [16260730.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1593-8 [16533786.001]
  • [Cites] Nature. 2006 Mar 30;440(7084):702-6 [16572177.001]
  • [Cites] Development. 2006 Jun;133(12):2359-69 [16687449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Mol Endocrinol. 1994 Aug;8(8):1006-20 [7997230.001]
  • (PMID = 17088539.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA109416; United States / NCI NIH HHS / CA / U01 CA084242; United States / NCI NIH HHS / CA / R01 CA017393; United States / NCI NIH HHS / CA / CA 17393; United States / NCI NIH HHS / CA / 1K24 CA109416; United States / NCI NIH HHS / CA / P50 CA083638; United States / NICHD NIH HHS / HD / HD 32212
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Immunoglobulin G; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / Testicular Hormones; 0 / anti-Mullerian hormone receptor; 0 / antineoplastic agent K 18; 776B62CQ27 / decitabine; 80497-65-0 / Anti-Mullerian Hormone; M801H13NRU / Azacitidine; P88XT4IS4D / Paclitaxel; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC1859945
  •  go-up   go-down


91. Matsuura Y, Kitajima M, Hachisuga T, Tanimoto A, Okura N, Kihara I: Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res; 2010 Aug;36(4):907-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings.
  • Malignant mixed müllerian tumor (MMMT) or carcinosarcoma of the female genital tract is a rare neoplasm.
  • Malignant ovarian tumor composed of müllerian epithelial tumor and malignant germ cell tumor is also rare, with most cases composed of endometrioid adenocarcinoma and yolk sac tumor.
  • Ovarian MMMT with malignant neuroectodermal components resembling immature teratoma is extremely rare.
  • We report a case of teratoid carcinosarcoma of the ovary occurring in a 40-year-old female.
  • Microscopic examination showed a heterogenous mixed tumor composed of malignant epithelial, malignant mesodermal and malignant neuroectodermal components.
  • This quite rare ovarian tumor closely resembled nasopharyngeal tumors described as 'teratoid carcinosarcoma' is biologically aggressive.
  • We report the fourth case of ovarian teratoid carcinosarcoma.
  • Further cases need to be accumulated to make diagnosis and to determine a successful treatment modality.
  • [MeSH-major] Carcinosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Ovary / pathology. Ovary / surgery

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666968.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


92. Cai KQ, Caslini C, Capo-chichi CD, Slater C, Smith ER, Wu H, Klein-Szanto AJ, Godwin AK, Xu XX: Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. PLoS One; 2009 Jul 31;4(7):e6454
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia.
  • GATA4 and GATA6 were found to be frequently lost in ovarian cancer, and the loss is proposed to account for dedifferentiation of the cancer cells.
  • METHODOLOGY/PRINCIPAL FINDINGS: We further investigated the expression of GATA4 and GATA6 in ovarian surface epithelial lesions and histological subtypes of ovarian carcinomas by immunostaining.
  • GATA4 and GATA6 were found to be absent in high percentages (80 to 90%) of serous, clear cell, and endometrioid ovarian cancer examined.
  • In contrast, both were found positive in 11 out of 12 cases of mucinous carcinomas, suggesting the expression of the GATA factors can distinguish mucinous cancer from other histological subtypes.
  • GATA4 was frequently lost in preneoplastic lesions such as morphologically normal inclusion cysts and epithelial hyperplasia adjacent to malignant cells.
  • The loss of GATA6 correlates closely with neoplastic morphological transformation of ovarian surface epithelia.
  • In culture, GATA4 expression was progressively reduced upon passaging primary ovarian surface epithelial cells, which correlated with changes in histone modification of the GATA4 locus.
  • A reduced GATA6 gene dosage as in GATA6 (+/-) mice led to an increased pre-neoplastic changes and inclusion cysts in the ovaries, suggesting the loss of GATA6 contributes to ovarian cancer development.
  • CONCLUSIONS/SIGNIFICANCE: This study suggests that the expression status of GATA4 and GATA6 may dictate distinct pathologic pathways leading to serous or mucinous ovarian carcinomas.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):309-22 [8660897.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):258-67 [16816378.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):281-8 [16337738.001]
  • [Cites] Oncogene. 2006 Aug 31;25(39):5446-61 [16607277.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):719-28 [16698071.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):13114-22 [17339320.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):161-3 [18455635.001]
  • [Cites] Dev Dyn. 2008 Oct;237(10):2820-9 [18816845.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Reprod Med. 2000 Feb;45(2):159-61 [10710752.001]
  • [Cites] J Biol Chem. 2000 Jun 30;275(26):19949-54 [10779506.001]
  • [Cites] Oncogene. 2000 Oct 5;19(42):4847-54 [11039902.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):38949-52 [11042222.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):116-20 [11242053.001]
  • [Cites] Histopathology. 2001 Feb;38(2):87-95 [11207821.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1555-64 [11927540.001]
  • [Cites] Cancer. 2002 May 1;94(9):2380-92 [12015763.001]
  • [Cites] EMBO J. 2002 Sep 16;21(18):4915-26 [12234931.001]
  • [Cites] Nature. 2002 Sep 26;419(6905):407-11 [12353038.001]
  • [Cites] Dev Biol. 2002 Nov 1;251(1):27-44 [12413896.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Nat Cell Biol. 2004 Jan;6(1):73-7 [14661024.001]
  • [Cites] EMBO J. 2004 Jan 14;23(1):138-49 [14685282.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Cell. 1980 Nov;22(2 Pt 2):629-32 [6160916.001]
  • [Cites] N Engl J Med. 1985 Feb 21;312(8):474-83 [3881673.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 [8961970.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1048-60 [9136932.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3579-90 [9832509.001]
  • [Cites] Development. 1999 Feb;126(4):723-32 [9895320.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):437-42 [10053122.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3104-13 [10340382.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):53-7 [1427402.001]
  • [Cites] Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):246-52 [8296829.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):647-8 [7846030.001]
  • [Cites] Recent Results Cancer Res. 1995;139:1-19 [7541145.001]
  • [Cites] Dev Biol. 2005 Oct 15;286(2):574-86 [16162334.001]
  • (PMID = 19649254.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA79716; United States / NCI NIH HHS / CA / R01 CA079716; United States / NCI NIH HHS / CA / R01 CA079716-10; United States / NCI NIH HHS / CA / #CA006927; United States / NCI NIH HHS / CA / R01 CA095071; United States / NCI NIH HHS / CA / CA75389; United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / CA079716-10; United States / NCI NIH HHS / CA / CA095071-06; United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / P50CA83638; United States / NCI NIH HHS / CA / R01 CA095071-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / GATA4 Transcription Factor; 0 / GATA4 protein, human; 0 / GATA6 Transcription Factor; 0 / GATA6 protein, human
  • [Other-IDs] NLM/ PMC2715102
  •  go-up   go-down


93. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases.
  • Information on ovarian metastasis of carcinoma of the extrahepatic bile ducts and gallbladder is limited.
  • The patients ranged from 21 to 87 years (mean, 59 years); 7 presented to gynecologists with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • All but one case had bilateral ovarian involvement.
  • The thirty-one ovarian lesions included twenty-nine grossly abnormal ovaries that were enlarged (range, 3.0-16.5 cm, mean, 9.4 cm) and 2 ovaries with only microscopic involvement.
  • Microscopically, ovarian surface implants were seen in 66%, multinodular growth in 58%, and infiltrative stromal invasion in 81%.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Signet ring cells were present in sufficient quantity for a diagnosis of Krukenberg tumor in four tumors.
  • Colloid-type carcinoma was observed at least focally in 3 tumors.
  • Nonmucinous carcinomatous components included adenocarcinoma with high-grade endometrioid-like morphology in 2 cases, papillary adenocarcinoma simulating mixed müllerian epithelial adenocarcinoma in 1, and undifferentiated carcinoma in 2.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Mulvany NJ, Mitchell G, Allen DG: Adenocarcinoma cells in Pap smears. Pathology; 2009;41(5):411-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma cells in Pap smears.
  • Adenocarcinomas of the cervix, endometrium, fallopian tube and ovary may present with malignant cells in a Pap smear.
  • The cell arrangement, pattern of cell spread and the smear background reflect the pathway by which the malignant cells involve the cervix.
  • Consideration of all of these points in conjunction with an appreciation of the classical cytomorphology of endometrioid, serous and clear cell carcinomas should allow a correct diagnosis of extrauterine adenocarcinoma with a high degree of probability.
  • [MeSH-major] Adenocarcinoma / diagnosis. Genital Neoplasms, Female / diagnosis. Papanicolaou Test. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900079.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 106
  •  go-up   go-down


95. Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, Miyatake T, Fujita M, Lee CM, Morimoto K, Fujimoto M, Kimura T, Naka T: Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer; 2009 Nov 15;125(10):2316-22
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
  • Clear cell carcinoma (CCC) of the ovary is known to be highly resistant to platinum-based chemotherapy.
  • Enhanced expression of Annexin A4 (Anx A4) was identified in ovarian CCC cells using 2-D differential gel electrophoresis (2D-DIGE) and mass spectrometry.
  • Immunohistochemical analysis of Anx A4 was performed in 126 epithelial ovarian cancer tissue samples and demonstrated significantly elevated levels of Anx A4 protein levels in ovarian CCC tumors compared with ovarian serous and endometrioid tumors (p < 0.01).
  • Anx A4-transfected ovarian non-CCC cells were more resistant to carboplatin (IC50 = 42 microM) compared with control cells (IC50 = 23 microM) as determined by modified MTT assay.
  • Expression of Anx A4 is elevated in ovarian CCC tumors and is associated with chemoresistance in cultured ovarian cancer cells.
  • These results demonstrate that Anx A4 confers chemoresistance in ovarian cancer cells in part by enhancing drug efflux.
  • Thus, Anx A4 may represent a novel therapeutic target of chemoresistance in patients with ovarian CCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Annexin A4 / metabolism. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19598262.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A4; 0 / Antineoplastic Agents; 0 / RNA, Messenger; BG3F62OND5 / Carboplatin
  •  go-up   go-down


96. García-Galvis OF, Cabrera-Ozoria C, Fernández JA, Stolnicu S, Nogales FF: Malignant Müllerian mixed tumor of the ovary associated with yolk sac tumor, neuroepithelial and trophoblastic differentiation (teratoid carcinosarcoma). Int J Gynecol Pathol; 2008 Oct;27(4):515-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant Müllerian mixed tumor of the ovary associated with yolk sac tumor, neuroepithelial and trophoblastic differentiation (teratoid carcinosarcoma).
  • This paper reports a unique stage IV complex ovarian carcinosarcoma in a 69-year patient that had malignant mixed müllerian epithelial and mesenchymal components and also other malignant differentiation such as neuroectodermal (small cell, neuroendocrine, neuroglial, neuronal, and melanocytic) and endodermal (yolk sac tumor) tissues and trophoblastic cells.
  • It was different from a teratoma as it coexisted with, and possibly originated from, a somatic tumor, namely a characteristic endometrioid adenocarcinoma.
  • All neoplastic tissue patterns present in the neoplasm were malignant per se without an apparent gradient of maturation or presence of organoid structures.
  • [MeSH-major] Carcinosarcoma / pathology. Endodermal Sinus Tumor / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753971.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Shirley S, Devi VS, Krishnamurthy R, Nabhi MV, Majhi U, Selvaluxmy G: Endometrial adenocarcinoma involving both horns of a bicornuate uterus. J Cancer Res Ther; 2010 Jul-Sep;6(3):304-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma involving both horns of a bicornuate uterus.
  • We report a rare case of endometrial adenocarcinoma involving both horns of a bicornuate uterus in a postmenopausal woman.
  • Patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection following an initial positive diagnosis of well differentiated endometrioid adenocarcinoma on endometrial biopsy.
  • Incidentally, the left ovary revealed a well differentiated sertoli leydig cell tumor.
  • Endometrial carcinoma arising in malformed uterus is rare.
  • Its simultaneous occurrence with an ovarian sertoli leydig cell tumor has not been reported in English literature so far.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Uterus / abnormalities

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119258.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


98. Logani S, Oliva E, Arnell PM, Amin MB, Young RH: Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol; 2005 Jan;18(1):19-25
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
  • Distinguishing primary ovarian carcinoma, particularly endometrioid and mucinous subtypes, from metastatic colorectal carcinoma to the ovary is often difficult on histologic examination alone.
  • We evaluated a panel consisting of antibodies to CDX2, beta-catenin and P504S in 23 primary ovarian adenocarcinomas (13 mucinous and 10 endometrioid) and compared the findings to 22 metastatic colorectal adenocarcinomas (seven mucinous and 15 nonmucinous tumors with endometrioid-like morphology hereafter referred to as pseudo-endometrioid) to the ovary stained with the same panel.
  • In contrast, only three (13%) primary ovarian tumors expressed at least two markers and none expressed all three.
  • Strong (2+, 3+) and diffuse (>40%) expression for CDX2 was noted in 21 (95%) metastatic tumors and five (22%) primary ovarian tumors (three mucinous, two endometrioid).
  • P504S was similarly expressed in seven (32%) metastatic and none of the primary ovarian carcinomas.
  • Immunohistochemical expression of gene products and enzymes of colorectal carcinogenesis in some primary ovarian carcinomas suggest that the morphologic similarities between colorectal and mucinous/endometrioid carcinoma of the ovary extends to the genetic level, although differences in the level of expression exist between these tumors.
  • Diffuse expression of all three markers (CDX2, beta-catenin and P504S) in a tumor in the ovary was found to be virtually diagnostic of metastasis from a colorectal primary in this study.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers / analysis. Colonic Neoplasms / pathology. Colorectal Neoplasms / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cytoskeletal Proteins / analysis. Diagnosis, Differential. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Racemases and Epimerases / analysis. Trans-Activators / analysis. beta Catenin

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15389251.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Homeodomain Proteins; 0 / Trans-Activators; 0 / beta Catenin; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


99. Brinton LA, Sakoda LC, Frederiksen K, Sherman ME, Kjaer SK, Graubard BI, Olsen JH, Mellemkjaer L: Relationships of uterine and ovarian tumors to pre-existing chronic conditions. Gynecol Oncol; 2007 Dec;107(3):487-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationships of uterine and ovarian tumors to pre-existing chronic conditions.
  • METHODS: Using record linkage techniques, we assessed the relationships between hospital and outpatient admissions for gallbladder disease, diabetes, hypertension, thyroid diseases and obesity and the subsequent development of uterine and ovarian cancers in Denmark between 1978 and 1998.
  • Based on a subsample of more than 99,000 women, including 1398 uterine and 2491 ovarian cancers, we derived relative risks (RRs) and 95% confidence intervals (CIs) associated with overall and histology-specific cancer risks after adjustment for age, calendar time and reproductive characteristics.
  • Although the "usual types" of endometrial cancer largely accounted for the observed associations, there was some evidence that uterine sarcomas (n=137) were related to prior diagnoses of thyroid diseases (2.78, 1.41-5.50).
  • In contrast, ovarian cancers were not strongly related to most documented chronic diseases.
  • An association of obesity and endometrioid ovarian cancer was not identified.
  • [MeSH-major] Chronic Disease / epidemiology. Ovarian Neoplasms / epidemiology. Uterine Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Coping with Chronic Illness.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):288-96 [12151152.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):347-55 [17357139.001]
  • [Cites] Gynecol Oncol. 1985 Jun;21(2):228-34 [3988136.001]
  • [Cites] Nutr Cancer. 1995;23(2):141-9 [7644383.001]
  • [Cites] Arch Intern Med. 1995 Sep 25;155(17):1868-72 [7677553.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):717-24 [8616764.001]
  • [Cites] Am J Epidemiol. 1996 Aug 15;144(4):363-72 [8712193.001]
  • [Cites] Cancer Causes Control. 1996 Nov;7(6):605-25 [8932921.001]
  • [Cites] Ann Epidemiol. 1997 Jan;7(1):46-53 [9034406.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):360-3 [9139868.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1360-5 [9308706.001]
  • [Cites] Mod Pathol. 1997 Oct;10(10):963-8 [9346174.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5077-85 [9371506.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1634-7 [9389926.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):253-7 [9648597.001]
  • [Cites] Am J Epidemiol. 1998 Aug 1;148(3):234-40 [9690359.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):539-42 [10225441.001]
  • [Cites] Dan Med Bull. 1999 Jun;46(3):263-8 [10421985.001]
  • [Cites] Ann Epidemiol. 2000 Jan;10(1):14-23 [10658685.001]
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):185-92 [10710204.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1172-7 [10904091.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Cancer Causes Control. 2000 Sep;11(8):707-11 [11065007.001]
  • [Cites] Am J Epidemiol. 2001 May 1;153(9):860-4 [11323316.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):568-74 [11709277.001]
  • [Cites] Obstet Gynecol Surv. 2002 Mar;57(3 Suppl):S1-7 [12074547.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):822-8 [12223425.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):669-76 [12640672.001]
  • [Cites] Oncology. 2003;64(4):341-5 [12759530.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1244-8 [12928351.001]
  • [Cites] Am J Epidemiol. 2003 Oct 1;158(7):629-38 [14507598.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1697-704 [14583772.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):262-8 [14639613.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1797-800 [14652242.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1515-21 [15042687.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):607-12 [15066926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):748-52 [15159305.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):431-6 [15228415.001]
  • [Cites] Oncology. 2004;67(1):54-9 [15459496.001]
  • [Cites] N Engl J Med. 1976 Jun 3;294(23):1262-7 [177870.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1055-60 [333120.001]
  • [Cites] Gynecol Oncol. 1978 Oct;6(5):451-8 [738623.001]
  • [Cites] Am J Obstet Gynecol. 1980 May 1;137(1):85-91 [7369293.001]
  • [Cites] Maturitas. 1980 Oct;2(3):185-90 [7442552.001]
  • [Cites] Gynecol Oncol. 1981 Feb;11(1):8-16 [6259021.001]
  • [Cites] Am J Obstet Gynecol. 1985 Apr 1;151(7):899-905 [3985056.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jan;156(1):20-3 [3799753.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Feb;24(2):189-94 [3356205.001]
  • [Cites] Jpn J Cancer Res. 1988 Sep;79(9):997-1004 [3142839.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Oct;25(10):1451-6 [2591436.001]
  • [Cites] Am J Obstet Gynecol. 1990 Jan;162(1):148-54 [2301483.001]
  • [Cites] Int J Cancer. 1991 Sep 30;49(3):362-7 [1917134.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):567-71 [1537622.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1317-25 [1442985.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):199-204 [7686914.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):321-7 [8348055.001]
  • [Cites] Jpn J Cancer Res. 1994 Apr;85(4):346-50 [8200846.001]
  • [Cites] Ann Chir Gynaecol Suppl. 1994;208:20-4 [8092764.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):950-3 [7947103.001]
  • [Cites] Hypertension. 1999 Aug;34(2):320-5 [10454461.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):520-30 [15661246.001]
  • [Cites] Fam Pract. 2005 Oct;22(5):548-53 [15964871.001]
  • [Cites] Int J Epidemiol. 2005 Dec;34(6):1284-90 [16186164.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2929-35 [16365012.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):276-80 [17301260.001]
  • (PMID = 17825884.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010126-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS35834; NLM/ PMC2199881
  •  go-up   go-down


100. Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH, Nam JH: Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol; 2008 Sep;19(3):185-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues.
  • OBJECTIVE: To investigate the expression levels of histone deacetylase (HDAC) 1, 2, and 3 in ovarian cancer tissues and normal ovarian tissues.
  • METHODS: Randomly assigned each of six patients with serous, mucinous and endometrioid ovarian cancer were included.
  • Another six patients with normal ovarian tissue were included for comparison.
  • RT-PCR was performed to quantify the levels of HDACs1-3 mRNA in the cancer and normal tissues.
  • RESULTS: Increased mRNA expressions of HDCA1, HDAC 2 and HDAC 3 were detected in 83%, 67% and 83% of 18 cancer tissue samples, compared to normal tissue samples.
  • The relative densities of HDAC1 mRNA and HDAC3 mRNA in the serous, mucinous and endometrioid cancer tissues, and HDAC2 mRNA in serous cancer tissues were significantly higher than those of the normal tissues, respectively (p<0.05).
  • Overexpression of HDAC1, HDAC2 and HDAC3 proteins were detected in 94%, 72% and 83% of 18 cancer samples, respectively.
  • The relative densities of HDAC1 protein and HDAC3 protein in serous, mucinous and endometrioid cancer, and HDAC2 protein in serous and mucinous cancer tissues were significantly higher than those of normal tissues, respectively (p<0.05).
  • Most cancer tissues expressed moderate to strong staining of HDACs1, 2 and 3 in immunohistochemistry.
  • Staining of HDAC2 was weak in only one endometrioid cancer tissue.
  • CONCLUSION: HDACs1-3 are over expressed in ovarian cancer tissues and probably play a significant role in ovarian carcinogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 May 12;281(19):13548-58 [16533812.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):121-41 [10652267.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):257-67 [11668507.001]
  • [Cites] Nat Med. 2001 Apr;7(4):437-43 [11283670.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):889-99 [11231943.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2760-70 [15536623.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(19):8415-29 [16166625.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16191-201 [10748092.001]
  • [Cites] Trends Cell Biol. 1999 May;9(5):193-8 [10322454.001]
  • [Cites] Cell. 1997 Aug 22;90(4):595-606 [9288740.001]
  • [Cites] Am J Physiol. 1997 Apr;272(4 Pt 1):G705-12 [9142899.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):26-32 [15305372.001]
  • [Cites] Curr Biol. 2004 Jul 27;14(14):R546-51 [15268870.001]
  • [Cites] Cancer Cell. 2004 May;5(5):455-63 [15144953.001]
  • [Cites] J Mol Biol. 2004 Apr 16;338(1):17-31 [15050820.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):353-8 [14506733.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] J Cell Physiol. 2000 Jun;183(3):347-54 [10797309.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):10887-92 [10753885.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:84-100 [12724214.001]
  • (PMID = 19471575.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676472
  • [Keywords] NOTNLM ; HDAC1 / HDAC2 / HDAC3 / Ovarian cancer
  •  go-up   go-down






Advertisement